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A B S T R A C T
Background
Fluphenazine is a typical antipsychotic drug from the phenothiazine group of antipsychotics. It has been commonly used in the
treatment of schizophrenia, however, with the advent of atypical antipsychotic medications, use has declined over the years.
Objectives
To measure the outcomes (both beneﬁcial and harmful) of the clinical effectiveness, safety and cost-effectiveness of oral ﬂuphenazine
versus atypical antipsychotics for schizophrenia.
Search methods
We searched theCochraneCentral Register of Studies (25April 2013). For the economic search,we searched theCochrane Schizophrenia
Group Health Economic Database (CSzGHED) on 31 January 2014
Selection criteria
All randomised controlled trials (RCTs) comparing ﬂuphenazine (oral) with any other oral atypical antipsychotics.
Data collection and analysis
Review authors worked independently to inspect citations and assess the quality of the studies and to extract data. For homogeneous
dichotomous data we calculated the risk ratio (RR) and 95% conﬁdence interval (CI), and calculated the mean differences (MDs)
for continuous data. We assessed risk of bias for included studies and used GRADE (Grading of Recommendations Assessment,
Development and Evaluation) to rate the quality of the evidence.
Main results
Four studies randomising a total of 202 people with schizophrenia are included. Oral ﬂuphenazine was compared with oral amisulpride,
risperidone, quetiapine and olanzapine.
Comparing oral ﬂuphenazine with amisulpride, there was no difference between groups for mental state using the Brief Psychiatric
Rating Scale (BPRS) (1 RCT, n = 57, MD 5.10 95% CI -2.35 to 12.55, very low-quality evidence), nor was there any difference in
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numbers leaving the study early for any reason (2 RCTs, n = 98, RR 1.19 95% CI 0.63 to 2.28, very low-quality evidence). More people
required concomitant anticholinergic medication in the ﬂuphenazine group compared to amisulpride (1 RCT, n = 36, RR 7.82 95%
CI 1.07 to 57.26, very low-quality evidence). No data were reported for important outcomes including relapse, changes in life skills,
quality of life or cost-effectiveness.
Comparing oral ﬂuphenazine with risperidone, data showed no difference between groups for ’clinically important response’ (1 RCT,
n = 26, RR 0.67 95% CI 0.13 to 3.35, very low-quality evidence) nor leaving the study early due to inefﬁcacy (1 RCT, n = 25, RR
1.08 95% CI 0.08 to 15.46, very low-quality evidence). No data were reported data for relapse; change in life skills; quality of life;
extrapyramidal adverse effects; or cost-effectiveness.
Once again there was no difference when oral ﬂuphenazine was compared with quetiapine for clinically important response (1 RCT,
n = 25, RR 0.62 95% CI 0.12 to 3.07, very low-quality evidence), nor leaving the study early for any reason (1 RCT, n = 25, RR 0.46
95% CI 0.05 to 4.46, very low-quality evidence). No data were reported for relapse; clinically important change in life skills; quality of
life; extrapyramidal adverse effects; or cost-effectiveness.
Compared to olanzapine, ﬂuphenazine showed no superiority for clinically important response (1 RCT, n = 60, RR 1.33 95% CI 0.86
to 2.07, very low-quality evidence), in incidence of akathisia (1 RCT, n = 60, RR 3.00 95% CI 0.90 to 10.01, very low-quality evidence)
or in people leaving the study early (1 RCT, n = 60, RR 3.00 95% CI 0.33 to 27.23, very low-quality evidence). No data were reported
for relapse; change in life skills; quality of life; or cost-effectiveness.
Authors’ conclusions
Measures of clinical response andmental state donot highlight differences betweenﬂuphenazine and amisulpride, risperidone, quetiapine
or olanzapine. Largely measures of adverse effects are also unconvincing for substantive differences between ﬂuphenazine and the newer
drugs. All included trials carry a substantial risk of bias regarding reporting of adverse effects and this bias would have favoured the
newer drugs. The four small short included studies do not provide much clear information about the relative merits or disadvantages of
oral ﬂuphenazine compared with newer atypical antipsychotics.
P L A I N L A N G U A G E S U M M A R Y
Comparing effectiveness of an older antipsychotic (oral fluphenazine) with newer antipsychotics for treating schizophrenia
Introduction
People with schizophrenia often hear voices or see things (hallucinations) and have strange beliefs (delusions). It is a distressing and
debilitating illness. The main treatment for schizophrenia is antipsychotic drugs. Fluphenazine is an older antipsychotic drug ﬁrst
formulated in the 1950s, effective for treating the psychoses of schizophrenia. However ﬂuphenazine can cause some serious side
effects, particularly movement disorders, and is known to lower people’s mood. Fluphenazine is inexpensive but the arrival of newer
antipsychotic drugs with fewer movement disorder side effects reduced its use and market share.
Methods
An electronic search of Cochrane Schizophrenia’s register of studies was carried out in 2013. Review authors looked for trials that
randomised people with schizophrenia to receive either oral ﬂuphenazine or an atypical antipsychotic. Four studies with a total of 202
people with schizophrenia could be included. The trials compared ﬂuphenazine with either amisulpride, risperidone, quetiapine or
olanzapine.
Results
Data showed oral ﬂuphenazine is no better or worse in improving mental state than amisulpride but more people receiving oral
ﬂuphenazine did need to take additional anticholinergic medication (drugs used to help relieve a range of symptoms such as involuntary
movements of the muscles, high blood pressure and insomnia).
Data from the trials comparing oral ﬂuphenazine with either risperidone, quetiapine or olanzapine also showed no superiority between
the treatment groups for clinical improvement. Only the trial comparing oral ﬂuphenazine with olanzapine provided adverse-effects
data. Again, incidence of akathisia, a movement disorder, was similar between treatment groups.
Quality of evidence
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Evidence from these few trials is poor, of low quality and involves a small number of participants. It does not provide clear overall
information about whether oral ﬂuphenazine is better or worse than atypical antipsychotic drugs for treating people with schizophrenia.
Data were not available for important outcomes such as such, relapse, hospital admission, satisfaction, costs and quality of life. Adverse-
effects data were poorly reported. Future large-scale research should report on these important outcomes.
Conclusions
Fluphenazine is low cost and widely available, so is likely to remain one of the most widely used treatments for schizophrenia worldwide.
However, evidence currently available from randomised controlled trials about its effectiveness compared to atypical antipsychotics is
unclear.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
FLUPHENAZINE (ORAL) compared to AM ISULPRIDE for schizophrenia
Patient or population: pat ients with schizophrenia
Settings: Austria & EU
Intervention: FLUPHENAZINE (ORAL)
Comparison: AMISULPRIDE
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
AM ISULPRIDE FLUPHENAZINE
(ORAL)
M ental state: Average
endpoint score BPRS
total score - short term
(up to 12 weeks) (high
= poor)
Brief Psychiatric Rat-
ing Scale (BPRS). Scale
f rom: 0 to 108.
Follow-up: 3 weeks
The mean mental state:
average endpoint score
BPRS total score - short
term (up to 12 weeks)
(high = poor) in the con-
trol groups was
37.2 points
The mean mental state:
average endpoint score
BPRS total score - short
term (up to 12 weeks)
(high = poor) in the in-
tervent ion groups was
5.1 higher
(-2.35 to 12.55 higher)
57
(1 study)
⊕©©©
very low1,2
Relapse (long term) -
not reported
See comment See comment Not est imable - See comment No study reported this
outcome
Clini-
cally important change
in life skills (long term)
- not measured
See comment See comment Not est imable - See comment No study measured this
outcome
Quality of life (long
term) - not measured
See comment See comment Not est imable - See comment No study measured this
outcome
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Adverse effects: Ex-
trapyramidal effects
- concomitant anti-
cholinergic medication
- short term (up to 12
weeks)
Part icipants requir-
ing concomitant ant i-
cholinergic medicat ion
Follow-up: 3 weeks
53 per 10003 412 per 1000
(56 to 1000)
RR 7.82
(1.07 to 57.26)
36
(1 study)
⊕©©©
very low2,4
Leaving the study early
- any reason - short
term (up to 12 weeks)
Follow-up: 3 weeks
M oderate RR 1.19
(0.63 to 2.28)
98
(2 studies)
⊕©©©
very low2,4
10 per 10003 33 per 1000
(1 to 768)
Cost-effectiveness
(long term) - not mea-
sured
See comment See comment Not est imable - See comment No study measured this
outcome
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Risk of bias: rated ’serious’ - randomisat ion methods not clearly stated; not all outcomes reported, not all part icipants
accounted for. Only one small study included (Boyer 1987, n = 62).
2 Imprecision: rated ’very serious’ - few part icipants, few events, leading to uncertainty in the precision of est imate of ef fect.
3 Control risk: mean baseline risk presented f rom single study.
4 Risk of bias: rated ’serious’ - randomisat ion methods not clearly stated; not all outcomes reported, sponsored by
pharmaceut ical company. Only one small study included (Saletu 1994, n = 40).
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B A C K G R O U N D
Description of the condition
Schizophrenia is a psychotic disorder that can present with a va-
riety of psychotic, cognitive and affective symptoms. It generally
follows a chronic course with acute relapses and (often partial) re-
mission. Schizophrenia is diagnosed in approximately 15.2 people
per 100,000 per year (McGrath 2008). The prevalence is higher, at
4.6 per 1000 (Saha 2005), which is another sign of the chronicity
of the condition. Heritability studies indicate a signiﬁcant genetic
component to the aetiology, however attempts to discover genes
that directly cause schizophrenia have not been fruitful. Many
environmental risk factors (such as urbanicity, deprivation, mi-
grant status, fetal anoxia, childhood abuse, cannabis misuse etc.)
have been shown to increase the risk of developing schizophrenia.
Hence, it is currently hypothesised that the aetiology is a poly-
genic susceptibility to schizophrenia in individuals, which inter-
acts with environmental risk factors. Research is increasingly fo-
cusing on these genetic and environmental interactions (van Os
2008). Symptoms are often sub-divided into ’positive’ and ’nega-
tive’ symptoms: positive symptoms include delusions (ﬁxed false
beliefs) and hallucinations (perceptions in the absence of an ex-
ternal stimulus). Negative symptoms are harder to deﬁne but of-
ten involve reductions in emotional and executive functioning, for
example ﬂattened affect, self-neglect, social isolation and apathy.
Morbidity is considerable, with the majority of sufferers unable to
work (Marvaha 2004). There is also increased mortality - partic-
ularly due to suicide (Healy 2012).
Description of the intervention
Antipsychotics are the most effective available treatment for
schizophrenia and are most effective at treating the positive symp-
toms of schizophrenia, however they are poorer at treating the
negative symptoms (Kane 1986). Antipsychotics can be classiﬁed
in a number of ways; commonly they are divided into typical and
atypical groups. Fluphenazine, developed by BristolMyers-Squibb
and approved by the US Food and Drug Administration (FDA)
in 1959, is a typical antipsychotic piperazine drug from the phe-
nothiazine group of antipsychotics. It is available as a tablet, short-
acting injection or long-acting injection. Originally, ﬂuphenazine
was used in Britain for the treatment of anxiety, until American re-
ports highlighted its potential for the treatment of psychotic illness
(Darling 1959; Millar 1963). Since then, it has been commonly
used in the treatment of schizophrenia; it is acknowledged as an es-
sential medicine by the World Health Organization (WHO) and
widely used internationally (WHO 2005). However, with the ad-
vent of atypical antipsychotic medications, use has declined over
the years.
How the intervention might work
Multiple lines of evidence point to an excess of dopaminer-
gic neuro-transmission in schizophrenia. All antipsychotics are
thought to be effective by reducing dopamine receptor activity,
usually by dopamine blockade in the mesolimbic area of the brain
(Grace 1991). Fluphenazine ( 2-[4-[3-[2-(triﬂuoromethyl)-10H-
phenothiazin-10-yl]propyl]piperazin-1-yl]ethanol, Figure 1) is a
high-potency D2 antagonist and also blocks D1a receptors post-
synaptically (Seeman 2002). It is not wholly speciﬁc: this and
other receptor activities account for its side-effect proﬁle. These
side effects range from hypotension secondary to alpha-adrener-
gic blockade, anticholinergic symptoms and extrapyramidal side
effects (EPSEs) (tardive dyskinesia, muscle rigidity, tremor, dysto-
nias and akathisia). It can also induce the neuroleptic malignant
syndrome. It has variable inter-individual bioavailability and un-
dergoes extensive ﬁrst-pass metabolism. Peak plasma levels occur
within hours and half-life is approximately 15 hours (Dencker
1988; Dysken 1981).
Figure 1. Fluphenazine structure
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Why it is important to do this review
Recent guidelines support the use of atypical antipsychotics as the
ﬁrst-line treatment in schizophrenia (APA 2004). Pharmaceutical
companies have marketed atypical medications as being superior
to typicals in terms of their efﬁcacy and tolerability (Kendall 2011),
whereas recent trials dispute this supposed advantage (Jones 2006;
Leucht 2009; Lieberman 2005). It is acknowledged that typical
drugs may have a higher propensity for EPSEs than many atypi-
cal drugs, many of which are more likely to induce the metabolic
syndrome. However, EPSEs can often be avoided by low-dose pre-
scribing. There are increasing concerns about the cardiovascular
risks associated with long-term use of atypical antipsychotics. Ad-
ditionally, it is the inexpensive typical antipsychotics that are more
heavily used instead of the more expensive atypical options in the
developing world. It is the accumulation of such factors that have
renewed interest in researching the efﬁcacy and tolerability of typi-
cal antipsychotics. Currently there is a lack of research evidence on
ﬂuphenazine versus atypical antipsychotics and this review aims
to draw together the existing evidence.
In terms of the costs of schizophrenia, this was estimated at about
£6.7 billion in England in 2004/05, of which the direct costs
were £2 million while the indirect costs accounted for the rest
(Mangalore 2007). The cost of ﬂuphenazine (oral) itself is inexpen-
sive compared to other atypical antipsychotics, at £1.88 for a 10
milligram (mg) tablet. The maximum daily dose of ﬂuphenazine
(oral) is 10 mg per day, which costs £1.88 per day, or £56.40 per
month (ﬂuphenazine oral is not present in the BNF - the cost was
in US Dollars and was converted to GBP on 31st January 2014
at the prevailing exchange rate on that day). The atypical antipsy-
chotics in comparison are more expensive than typical antipsy-
chotics, with olanzapine available at £13.11 for 28 5 mg tablets,
and clozapine (Clozaril) at £21.56 for 28 100 mg tablets.
It is important to complement the clinical effectiveness of
ﬂuphenazine (oral) with its cost-effectiveness; Davies and col-
leagues (Davies 2007) conducted a study on cost-effectiveness
of the ﬁrst-generation antipsychotics (i.e. ﬂupentixol, triﬂuoper-
azine, chlorpromazine) and the second generation antipsychotics
(i.e. risperidone, olanzapine, amisulpride). The study ﬁndings ar-
gue that there is no evidence to suggest that atypical (second gen-
eration) antipsychotics are more cost-effective than typical (ﬁrst-
generation) antipsychotics.
This is one of a family of related Cochrane reviews (Table 1).
O B J E C T I V E S
Tomeasure the outcomes (both beneﬁcial and harmful) of the clin-
ical effectiveness, safety and cost-effectiveness of oral ﬂuphenazine
versus atypical antipsychotics for schizophrenia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled trials (RCTs). We planned to
include data from cross-over trials only until the point of the
ﬁrst cross-over as thereafter data tend to become unstable. If trials
were described as ’double-blind’ but implied randomisation, we
included them in a sensitivity analysis (see Sensitivity analysis).
We excluded quasi-randomised studies, such as those allocating
by alternate days of the week. Where people were given additional
treatments with oral ﬂuphenazine, we only included data if the
adjunct treatment was evenly distributed between groups and it
was only the oral ﬂuphenazine that was randomised.
With regards to selecting studies for economic evaluations, review
authors (SS and VF) categorised studies as follows.
Type A - Full economic evaluation (within the framework of
RCTs): studies that focus on cost-effectiveness analysis, cost-util-
ity analysis and cost-beneﬁt analysis.
Type B - Partial economic evaluation (within the framework of
RCTs): studies that focus on cost-analysis and cost-minimisation
studies of ﬂuphenazine (oral).
Type C - Randomised trials that reported limited informa-
tion, such as estimates of resources use or costs associated with
ﬂuphenazine (oral).
Types of participants
Adults (aged 18 and over) with schizophrenia or related disorders,
including schizophreniform disorder, schizoaffective disorder and
delusional disorder, again by any means of diagnosis. We excluded
children and people with dementing illnesses, depression and pri-
mary problems associated with substance misuse. We are inter-
ested in making sure that information is as relevant to the current
care of people with schizophrenia as possible so aimed to highlight
clearly the current clinical state (acute, early post-acute, partial re-
mission, remission) as well as the stage (prodromal, ﬁrst episode,
early illness, persistent) and whether the studies primarily focused
on people with particular problems (for example, negative symp-
toms, treatment-resistant illnesses).
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Types of interventions
1. Oral fluphenazine
Any dose or form of oral application (i.e. not depot or short-acting
parenteral).
2. Atypical oral antipsychotics
Any dose or form of oral atypical antipsychotics.
Types of outcome measures
We divided outcomes into short term (up to 12 weeks), medium
term (13 to 26 weeks) and long term (over 26 weeks).
Primary outcomes
1. Clinically important response (as defined by the
individual studies)
1.1 Global impression - ≥ 50% improvement on any relevant
rating scale
Secondary outcomes
1. Death
1.1 Suicide
1.2 Natural causes
2. Global state
2.1 Clinically important change in global state (as deﬁned by in-
dividual studies)
2.2 Average endpoint/change in global state score
2.3 Relapse (as deﬁned in each study)
3. Service outcomes
3.1 Hospitalisation/re-hospitalisation
3.2 Time to hospitalisation
4. Mental state
4.1 Clinically important change in general mental state
4.2 Average endpoint/change in general mental state score
4.3 Clinically important change in speciﬁc symptoms (positive/
negative symptoms and depression scores)
5. General functioning
5.1 Clinically important change in general functioning
5.2 Average endpoint/change in general functioning score
5.3 Clinically important change in speciﬁc aspects of functioning
(including social skills, life skills, employment)
5.4 Average endpoint/change in speciﬁc aspects of functioning
(including social skills, life skills, employment)
6. Quality of life
6.1 Clinically important change in quality of life
6.2 Average endpoint/change in quality of life score
7. Satisfaction with treatment
7.1 Clinically important change in levels of satisfaction
7.2 Average endpoint/change in satisfaction
8. Adverse effects - general and specific
8.1 Clinically important general/speciﬁc adverse effects
8.2 Average endpoint/change in general/speciﬁc adverse effect
score
9. Extrapyramidal adverse effects
9.1 Any clinically signiﬁcant extrapyramidal adverse effects
9.2 Any clinically signiﬁcant extrapyramidal side effects (EPSEs)
- as deﬁned by each study
9.3 Average score/change in EPSEs
9.4 Incidence of use of antiparkinson drugs
9.5 Dystonia
9.6 Akathisia
9.7 Akinesia
10. Leaving the study early - any reason
10.1 Leaving the study early - due to inefﬁcacy of the intervention
10.2 Leaving the study early due to side effects
11. Economic outcomes
11.1 Average change in total cost of medical and mental health
care
11.2 Total indirect and direct costs
11.3 Direct resource use:
11.3.1 Outpatients - number of contacts (GP consultation, psychia-
trist, psychologists, psychiatric nurse, counsellor, social worker)
11.3.2 Hospitalisation (taking battery of tests, patients’ physical, psy-
chiatric and psychological profile and psychological assessment, num-
ber of days, relapse)
11.3.3 Medication (different types of antipsychotics to include dose
and frequency, treatment of side effects)
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11.3.4Psychological therapies (different types of psychological therapies
to include session numbers and frequency)
11.3.5 Other resources (day centres, night shelter) and transportation
for medical care visits
11.4 Indirect resource use:
11.4.1 Family, relative and friends resources
11.4.2 Police, criminal justice system
11.4.3 Benefits paid, social security payments
11.4.4 Employment agency workers, absence from work, loss of pro-
ductivity
11.5 Cost-effectiveness ratios represented by the incremental cost-
effectiveness ratio (ICER)
11.6 Cost-utilities represented by incremental costs per quality-
adjusted life year (QALY) or disability adjusted life year (DALY)
11.7 Cost-beneﬁt represented by net Beneﬁt Ratio, others
12. ’Summary of findings’ table
Weused theGRADEapproach to interpret ﬁndings (Schünemann
2008) and used GRADE proﬁler (GRADEPRO) to import data
fromRevMan5 (Review Manager) to create ’Summary of ﬁndings’
tables. These tables provide outcome-speciﬁc information con-
cerning the overall quality of evidence from each included study
in the comparison, the magnitude of effect of the interventions
examined, and the sum of available data on all outcomes we rated
as important to patient care and decision making. We selected the
following main outcomes for inclusion in the ’Summary of ﬁnd-
ings’ table:
1. Clinically important response in mental state (short,
medium and long term)
2. Relapse (long term)
3. Clinically important change in life skills (long term)
4. Quality of life (long term)
5. Adverse effects, e.g. EPSEs (medium term)
6. Leaving the study early: any reason (medium term)
7. Cost-effectiveness (long term)
Search methods for identification of studies
Electronic searches
We searched the Central Register of Studies (25 April 2013) using
the phrase:
(“*clozapin*”:TI OR “* clozaril*”:TI OR “* leponex*”:TI OR
“*aripiprazole*”:TI OR “*olanzapin*”:TI OR “*lanzac*”:TI OR
“*zyprex*”:TI OR “*quetiapin*”:TI OR “*seroquel*”:TI OR
“*risperidon*”:TI OR “*belivon*”:TI OR “*risperdal*”:TI OR
“*risperin*”:TI OR “*rispolin*”:TI OR “*sertindol*”:TI OR
“*serdolect*”:TI OR “*serlect*”:TI OR “*ziprasidon*”:TI OR
“*zotepin*”:TI OR “*lodopin*”:TI OR “*nipolept*”:TI OR “*zo-
pite*”:TI OR “*setous*”:TI OR “*majorpin*”:TI OR “*remox-
iprid*”:TI OR “*roxiam*”:TI OR “*remidon*”:TI OR “*iloperi-
don*”:TI OR “*clozapin*”:AB OR “* clozaril*”:AB OR “* lep-
onex*”:AB OR “*aripiprazole*”:AB OR “*olanzapin*”:AB OR
“*lanzac*”:AB OR “*zyprex*”:AB OR “*quetiapin*”:AB OR
“*seroquel*”:AB OR “*risperidon*”:AB OR “*belivon*”:AB OR
“*risperdal*”:AB OR “*risperin*”:AB OR “*rispolin*”:AB OR
“*sertindol*”:AB OR “*serdolect*”:AB OR “*serlect*”:AB OR
“*ziprasidon*”:AB OR “*zotepin*”:AB OR “*lodopin*”:AB OR
“*nipolept*”:ABOR “*zopite*”:ABOR “*setous*”:AB OR “*ma-
jorpin*”:AB OR “*remoxiprid*”:AB OR “*roxiam*”:AB OR
“*remidon*”:AB OR “*iloperidon*”:AB OR “*clozapine*” null
“*clozapin*” OR “* clozaril*” OR “* leponex*” null “*aripipra-
zole*” OR “*olanzapin*” OR “*lanzac*” OR “*zyprex*” OR
“*quetiapin*” OR “*seroquel*” OR “*risperidon*” OR “*be-
livon*” OR “*risperdal*” OR “*risperin*” OR “*rispolin*” OR
“*sertindol*” OR “*serdolect*”OR “*serlect*”OR “*ziprasidon*”
OR “*zotepin*” OR “*lodopin*” OR “*nipolept*” OR “*zo-
pite*” OR “*setous*” OR “*majorpin*” OR “*remoxiprid*” OR
“*roxiam*” OR “*remidon*” OR “*iloperidon*” OR “*atypi-
cal*”:TI OR “*atypical*”:TI OR “*atypical*”:AB OR “*atypi-
cal*”) AND (“*ﬂuphen*”:TI OR “*ﬂuphen*”:TI OR “*ﬂufen*”:
TI OR “*ﬂufen*”:TI OR “*lyogen*”:TI OR “*lyogen*”:TI
OR “*prolixin*”:TI OR “*prolixin*”:TI OR “*siqualon*”:TI
OR “*siqualon*”:TI OR “*modec*”:TI OR “*moditen*”:TI
OR “*ﬂuphen*”:AB OR “*ﬂufen*”:AB OR “*lyogen*”:AB OR
“*prolixin*”:AB OR “*siqualon*”:AB OR “*modec*”:AB OR
“*moditen*”:AB OR “*ﬂuphen*” OR “*ﬂufen*” OR “*lyo-
gen*” OR “*prolixin*” OR “*siqualon*” OR “*modec*” OR
“*moditen*”)
2. Economic study search of Cochrane Schizophrenia Group
Health Economic Database (2013)
For the economic search, we replicated the above strategy in
the Cochrane Schizophrenia Group Health Economic Database
(CSzGHED) on 31 January 2014. The database of studies relates
to cost-effectiveness of schizophrenia treatments. This database
was constructed from systematic searches of four databases:Health
Economic Evaluation Database (HEED), National Health Ser-
vicesHealth Economic Database (NHS EED), Cost-Effectiveness
AnalysisRegistry (CEA) andEconLit aswell as Cochrane Registry.
Searching other resources
1. Reference searching
We inspected references of all included studies for further relevant
studies.
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2. Personal contact
We contacted the ﬁrst author of each included study for informa-
tion regarding unpublished trials.
3. Pharmaceutical companies
We contacted relevant pharmaceutical companies to obtain more
information or data on unpublished trials if appropriate.
Data collection and analysis
Selection of studies
Review author JS independently inspected citations from the
searches and identiﬁed relevant abstracts. Review author SS inde-
pendently re-inspected a random 20% sample to ensure reliability.
Where disputes arose, we acquired the full report for more detailed
scrutiny. JS obtained and inspected full reports of the abstracts
meeting the review criteria. Again, SS re-inspected a random 20%
of full reports in order to ensure reliable selection. Where it was
not possible to resolve disagreement by discussion, we attempted
to contact the authors of the study for clariﬁcation.
For the selectionof economic studies, review authorsVF and SS in-
spected all retrieved citations identiﬁed by the economic database
search, and where disputes arose, we acquired the full report for
further inspection.
Data extraction and management
1. Extraction
Review author BGL, SZ, JX, independently extracted data from
included studies, and SS made a random 20% check to ensure
reliability. Again, we discussed any disagreement. We extracted
data presented only in graphs and ﬁgures whenever possible, but
included the data only if the two review authors independently
had the same result.
For the economic analysis, had Type A and B studies been iden-
tiﬁed (see Types of studies), review authors VF ad SS would have
investigated whether appraisal had already been undertaken by
NHS EED using their search tool derived for this purpose. If ap-
praisal had not been undertaken, VF and SS would have applied
the NHS EED tool to the data. For Type C studies, we planned
to extract outcome data directly from the already-included effec-
tiveness studies.
2. Management
2.1 Forms
We extracted data onto standard, simple forms.
2.2 Scale-derived data
We included continuous data from rating scales only if:
a) the psychometric properties of the measuring instrument were
described in a peer-reviewed journal (Marshall 2000); and
b) the measuring instrument had not been written or modiﬁed by
one of the trialists for that particular trial.
Ideally, the measuring instrument should either be i) a self-report
or ii) completed by an independent rater or relative (not the ther-
apist). We realise that this is not often reported clearly and noted
this in the Description of studies section.
2.3 Endpoint versus change data
There are advantages to both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. On the other hand, calculation of change needs two
assessments (baseline and endpoint), which can be difﬁcult in
unstable and difﬁcult tomeasure conditions such as schizophrenia.
We decided primarily to use endpoint data and only use change
data if the former were not available. We combined endpoint and
change data in the analysis as we preferred mean differences (MD)
rather than standardised mean differences (SMD) throughout (
Higgins 2011).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we aimed to apply the following
standards to relevant data before inclusion.
Studies, N > 200
We entered useable data from studies of at least 200 participants,
for example, in the analysis irrespective of the following rules,
because skewed data pose less of a problem in large studies.
Change data
We also entered all useable change data as when continuous data
are presented on a scale that includes a possibility of negative values
(such as change data), it is difﬁcult to tell whether data are skewed
or not.
Endpoint data, N < 200
(a)When a scale started from the ﬁnite number zero, we subtracted
the lowest possible value from the mean and divided this by the
standard deviation (SD). If this value was lower than 1, it would
have strongly suggested a skew and we excluded these data. If
this ratio was higher than 1 but below 2, there is a suggestion of
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skew. We entered these data and tested whether their inclusion or
exclusion changed the results substantially. Finally, if the ratio was
larger than 2 we included these data, because skew was less likely
(Altman 1996; Higgins 2011).
b) If a scale started from a positive value (such as the Positive and
Negative Syndrome Scale (PANSS) (Kay 1986), which can have
values from 30 to 210), we modiﬁed the calculation described
above to take the scale starting point into account. In these cases
skew is present if 2 SD > (S-S min), where S is the mean score and
’S min’ is the minimum score.
2.5 Common measure
To facilitate comparison between trials, we intended to convert
variables that can be reported in different metrics, such as days in
hospital (mean days per year, per week or permonth) to a common
metric (e.g. mean days per month).
2.6 Conversion of continuous to binary
Where possible, we made efforts to convert outcome measures
to dichotomous data. This can be done by identifying cut-off
points on rating scales and dividing participants accordingly into
’clinically improved’ or ’not clinically improved’. It is generally
assumed that if there is a 50% reduction in a scale-derived score
such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962)
or the PANSS (Kay 1986), this could be considered as a clinically
signiﬁcant response (Leucht 2005; Leucht 2005a).
2.7 Direction of graphs
We entered data in such a way that the area to the left of the line
of no effect indicates a favourable outcome for oral ﬂuphenazine.
Where keeping to this makes it impossible to avoid outcome ti-
tles with clumsy double-negatives (e.g. ’Not un- improved’) we
reported data where the left of the line indicates an unfavourable
outcome. We noted this in the relevant graphs.
Assessment of risk of bias in included studies
Again BGL and JS worked independently to assess risk of bias by
using criteria described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011) to assess trial quality. This
set of criteria is based on evidence of associations between over-
estimate of effect and high risk of bias of the article such as se-
quence generation, allocation concealment, blinding, incomplete
outcome data and selective reporting.
If the raters disagreed, we made the ﬁnal rating by consensus with
SS.
We noted the level of risk of bias in both the text of the review
and in the ’Summary of ﬁndings’ tables.
This review also aimed to assess the overall methodological quality
of each study included in the economic evaluation. We planned to
use the checklist developed by Drummond 1996 and the CHEC
criteria list (Evers 2005) for Type A and B studies. Had we found
any economic studies of Type A or B level, this would have been
noted in the summary as well as in a separate table.
Measures of treatment effect
1. Binary data
For binary outcomeswe calculated a standard estimationof the risk
ratio (RR) and its 95% conﬁdence interval (CI). It has been shown
that RR is more intuitive (Boissel 1999) than odds ratios and that
odds ratios tend tobe interpreted asRRby clinicians (Deeks 2000).
The number needed to treat/harm (NNTB/NNTH) statistic with
its conﬁdence intervals is intuitively attractive to clinicians but
is problematic both in its accurate calculation in meta-analyses
and interpretation (Hutton 2009). For binary data presented in
the ’Summary of ﬁndings’ table/s, where possible, we calculated
illustrative comparative risks.
2. Continuous data
For continuous outcomes we estimated the mean difference (MD)
between groups. We preferred not to calculate effect size measures
(standardised mean difference (SMD)). However, if in future ver-
sions of this review, if scales of very considerable similarity are
used, we will presume there is a small difference in measurement,
and we will calculate effect size and transform the effect back to
the units of one or more of the speciﬁc instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice), but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for intra-class correlation in clustered studies, leading to a ’unit
of analysis’ error (Divine 1992) whereby P values are spuriously
low, conﬁdence intervals unduly narrow and statistical signiﬁcance
overestimated. This causes type I errors (Bland 1997; Gulliford
1999).
We did not identify any cluster-randomised studies; however, in
future version of this review, and where we identify studies that
have not accounted for clustering in primary studies, we will
present data in a table, with a (*) symbol to indicate the presence
of a probable unit of analysis error. In subsequent versions of this
review we will seek to contact ﬁrst authors of studies to obtain
intra-class correlation coefﬁcients (ICCs) for their clustered data
and to adjust for this by using acceptedmethods (Gulliford 1999).
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Where clustering has been incorporated into the analysis of pri-
mary studies, we will present these data as if from a non-cluster
randomised study, but adjust for the clustering effect.
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’design
effect’. This is calculated using the mean number of participants
per cluster (m) and the ICC (design effect = 1+(m-1)*ICC) (
Donner 2002). If the ICC is not reported it would be assumed to
be 0.1 (Ukoumunne 1999).
If cluster studies have been appropriately analysed, taking into ac-
count ICCs and relevant data documented in the report, synthe-
sis with other studies would be possible using the generic inverse
variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. It oc-
curs if an effect (e.g. pharmacological, physiological or psycho-
logical) of the treatment in the ﬁrst phase is carried over to the
second phase. As a consequence, on entry to the second phase
the participants can differ systematically from their initial state
despite a wash-out phase. For the same reason cross-over trials are
not appropriate if the condition of interest is unstable (Elbourne
2002). We did not identify any cross-over studies; however, in fu-
ture versions of this review where such studies are identiﬁed, as
both effects are very likely in severe mental illness, we will only
use data from the ﬁrst phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involves more than two treatment arms, if relevant,
we presented the additional treatment arms in comparisons. If
data were binary we simply added and combined these within
the two-by-two table. If data were continuous, we combined data
following the formula in section 7.7.3.8 (Combining groups)
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Dealing with missing data
1. Overall loss of credibility
At some degree of loss to follow-up, data must lose credibility (Xia
2009). We chose that, for any particular outcome, should more
than 50% of data be unaccounted for, we would not reproduce
these data or use them within analyses. If, however, more than
50% of those in one arm of a study were lost, but the total loss was
less than 50%, we planned to address this within the ’Summary of
ﬁndings’ table/s by downgrading quality. Finally, we also planned
to downgrade quality within the ’Summary of ﬁndings’ table/s
should loss be 25% to 50% in total. Such high losses were not
experienced in the included studies.
2. Binary
In the case where attrition for a binary outcome was between
0% and 50% and where these data were not clearly described,
we presented data on a ’once randomised always analyse’ basis
(an intention-to-treat analysis). Those leaving the study early are
all assumed to have the same rates of negative outcome as those
who completed, with the exception of the outcome of death and
adverse effects. For these outcomes, the rate of those who stay
in the study - in that particular arm of the trial - were used for
those who did not. We undertook a sensitivity analysis to test how
prone the primary outcomes were to change when data only from
people who completed the study to that point were compared to
the intention-to-treat analysis using the above assumptions.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome was between
0% and 50%, and data only from people who completed the study
to that point were reported, we reproduced these data.
3.2 Standard deviations
If standard deviations (SDs) were not reported, ﬁrst, we tried to
obtain the missing values from the authors. If not available, where
there are missing measures of variance for continuous data, but
an exact standard error (SE) and conﬁdence intervals are available
for group means, and either P value or ’t’ value are available for
differences in mean, we can calculate them according to the rules
described in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011). When only the SE is reported, SDs
are calculated by the formula SD = SE * square root (n). Chapters
7.7.3 and 16.1.3 of the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011) present detailed formulae for es-
timating SDs from P values, t or F values, conﬁdence intervals,
ranges or other statistics. If these formulae do not apply, we can cal-
culate the SDs according to a validated imputation method which
is based on the SDs of the other included studies (Furukawa 2006).
Although some of these imputation strategies can introduce error,
the alternative would be to exclude a given study’s outcome and
thus to lose information. We did not impute any values, since we
did not identify any missing SDs in the included studies.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We simply inspected
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all studies for clearly outlying people or situations which we had
not predicted would arise. Had such situations or participant
groups arisen,wewould have fully discussed these.However,meta-
analysis was not possible, since all included studies compared var-
ious different atypical antipsychotics versus oral ﬂuphenazine.
2. Methodological heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We simply
inspected all studies for clearly outlyingmethodswhichwe had not
predicted would arise. When such methodological outliers arose
we fully discussed these.
3. Statistical heterogeneity
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
3.2 Employing the I2 statistic
We investigated heterogeneity between studies by considering the
I2 statistic alongside the Chi2 test P value. The I2 statistic provides
an estimate of the percentage of inconsistency thought to be due
to chance (Higgins 2003). The importance of the observed value
of I2 depends on i) the magnitude and direction of effects and ii)
the strength of evidence for heterogeneity (e.g. P value from Chi2
test or a conﬁdence interval for I2). We planned to interpret an I
2 estimate greater than or equal to around 50%, accompanied by
a statistically signiﬁcant Chi2 test, as evidence of substantial levels
of heterogeneity (Section 9.5.2 - Higgins 2011). Had substantial
levels of heterogeneity been found for the primary outcome, we
would have explored the reasons for this (Subgroup analysis and
investigation of heterogeneity).
Assessment of reporting biases
1. Protocol versus full study
Reporting biases arise when the dissemination of research ﬁnd-
ings is inﬂuenced by the nature and direction of results. These are
described in section 10.1 of the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011). We made attempts
to locate protocols for the included randomised trials. Had any
protocols been available, we would have compared the outcomes
in the protocol and in the published report.
2. Funnel plot
Reporting biases arise when the dissemination of research ﬁndings
is inﬂuenced by the nature and direction of results (Egger 1997).
These are again described in section 10 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).We are aware
that funnel plotsmay be useful in investigating reporting biases but
are of limited power to detect small-study effects. We did not use
funnel plots for outcomes since there were less than 10 included
studies.
Data synthesis
We understand that there is no closed argument for preference for
use of ﬁxed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies even if there is no statistically
signiﬁcant heterogeneity. There is, however, a disadvantage to the
random-effects model. It puts added weight onto small studies
which often are the most biased ones. Depending on the direction
of effect these studies can either inﬂate or deﬂate the effect size.
For this review, we chose a random-effects model for all analyses.
Handling of economic data
“It has been argued for many years that promoting effective care with-
out taking into account the cost of care and the value of any health
gain can lead to inefficient use of public and private funds allocated
to health care, which may indirectly result in harm for individuals
and the public” (Williams 1987).
We intended to summarise data from type A and type B studies and
summarise data according to the Cochrane Campbell Economic
Methods Group (Higgins 2011), and if information had been
available, a narrative abstract would have been presented for each
included study.
We anticipated that most studies would be Type C level of eco-
nomic evidence and that we would use data from such studies to
calculate a GBP value associated with the outcomes. These ap-
proximate values can be calculated by:
(a) using the Personal Social Services Research Unit (PSSRU -
NHS reference costs formental health services) calculationof £338
(weighted mean average of all adult mental health in-patient bed
days) per hospital bed day based in a UK NHS setting (PSSRU
2012); and
(b) assuming that one relapse equals one hospital admission, a me-
dian length of stay as 16 days, as per Hospital Episode Statistics
2012 (HES 2012; main speciality ‘adult mental illness’), we could
utilise results of the effects of the intervention that present service
use data for an adult ward as well as for relapse rates (HES is a
data warehouse containing details of all admissions, outpatient ap-
pointments and A&E attendances at NHS hospitals in England);
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(c) in terms of use of adjunctive medication, if the speciﬁc drug is
not mentioned then we would assume that the adjunctive medi-
cation used was phenobarbital and that it would be prescribed for
no longer than 14 days at an average dose of 120 mg per day; the
cost for this was obtained from the BNF which provides unit costs
for the medication;
(d) in terms of treatment for EPSEs, if the speciﬁc drug was not
mentioned, we would assume that for the treatment procyclidine
was used at a dose of 10 mg three times a day for 14 days; the cost
for this was obtained from the BNF which provides unit costs for
the medication
(e) in terms of treatment for akathisia, if the speciﬁc drug was not
mentioned, we would assume that for the treatment propranolol
was prescribed at a dose of 80 mg twice a day for 14 days; the cost
for this was obtained from the BNF which provides unit costs for
the medication;
(f ) in terms of treatment for depression, if the speciﬁc drug was
not mentioned, we would assume that for the treatment ﬂuoxetine
was prescribed at a dose of 20 mg once a day for 120 days; thee
cost for this was obtained from the BNF which provides unit costs
for the medication;
(g) in terms of epileptic ﬁts, we would assume that such ﬁts last for
less than ﬁve minutes (more than ﬁve minutes constitutes Status
Epilepticus as speciﬁed byNICE 2012), unless otherwise speciﬁed;
(h) in terms of treatment for agitation, if the speciﬁc drug was not
mentioned, we would assume that for the treatment lorazepam
was prescribed at a dose of 1 mg up to four times a day for three
days; the cost for this was obtained from the BNF which provides
unit costs for the medication.
We did not factor any associated costs (including cost and resource
use of treatment) prior to the relevant measured outcomes being
considered.We are using UKNHSPSSRU reference costs of 2012
as well as BNF costs from 2013 and therefore planned to present
the outcomes in terms of aGBP saving using relative risks obtained
from the effectiveness part of the review, which we have considered
to be a proxy for resource use.
The authors wish to emphasise the numerous assumptions that
have been made for the purposes of presenting economic data,
speciﬁcally of Type C studies:
1. the current included studies contributing to the Type C
studies were undertaken between the years of 1987 to 2005; and,
taking this into account;
2. the median length of stay and costs have been calculated
from current available data, that is, according to 2012 HES
costs, from primarily a UK NHS perspective; and
3. the GBP value data that are presented reﬂect a proxy
measure only; that is, the GBP value of the intervention effect on
the measured outcome, and not taking into account any costs or
resource use that may likely have been incurred prior to the
actual outcome (which includes, but is not limited to, costs and
resource use prior to intervention, the intervention itself and
post-intervention up to outcome).
We are aware that Cochrane systematic reviews are international
in context and in their understanding; however, we have adopted
a UK NHS perspective for the purposes of this review - partly
because we have been funded by the National Institute of Health
Research (NIHR) (NIHRCochrane ProgrammeGrant 2011, UK
Reference number: 10/4001/15) to undertake a series of economic
evaluations within systematic reviews.
“…[I]n the face of scarce resources, decision makers often need to
consider not only whether an intervention works, but also whether
its adoption will lead to a more efficient use of resources” (Higgins
2011).
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
1.1 Primary outcomes
We subgrouped analyses by length of treatment (short, medium
and long term).
1.2 Clinical state, stage or problem
Where possible, we reported data on subgroups of people in the
same clinical state, stage and with similar problems.
2. Investigation of heterogeneity
Had inconsistency been high, wewould have reported this. Should
this happen in future versions of this review, ﬁrst wewill investigate
whether the data have been entered correctly. Second, if the data
are correct, we will visually inspect the graph and successively
remove outlying studies to see if homogeneity is restored. For this
review, we decided that should this occur with data contributing
no more than around 10% of the total weighting to the summary
ﬁnding, we will present the data. If not, we will not pool the data
and discuss the issues. We know of no supporting research for this
10% cut-off but are investigating use of prediction intervals as an
alternative to this unsatisfactory state.
When unanticipated clinical or methodological heterogeneity are
obvious we will simply state hypotheses regarding these for future
reviews or versions of this review.Wedonot anticipate undertaking
analyses relating to these.
Sensitivity analysis
1. Implication of randomisation
We included trials in a sensitivity analysis if they were described in
some way as to imply randomisation. For the primary outcomes
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we included these studies, If their inclusion did not result in a sub-
stantive difference, they remained in the analyses. If their inclusion
did result in important, clinically signiﬁcant but not necessarily
statistically signiﬁcant differences, we did not add the data from
these lower quality studies to the results of the better trials, but
presented such data within a subcategory.
2. Assumptions for lost binary data
Where assumptions had to bemade regardingpeople lost to follow-
up (see Dealing with missing data), we compared the ﬁndings of
the primary outcomes when we use our assumption/s and when
we used data only from people who completed the study to that
point. If there was a substantial difference, we reported the results
and discussed them but continued to employ our assumption.
Where assumptions had to be made regarding missing SD data
(see Dealing with missing data), we compared the ﬁndings of the
primary outcomes when we used our assumption/s and when we
used data only from people who completed the study to that point.
We undertook a sensitivity analysis to test how prone results were
to change when completer-only data only were compared to the
imputed data using the above assumption. If there was a substan-
tial difference, we reported the results and discussed thembut con-
tinued to employ our assumption.
3. Risk of bias
We analysed the effects of excluding trials that are judged to be at
high risk of bias across one or more of the domains of randomi-
sation, allocation concealment, blinding and outcome reporting
for the meta-analysis of the primary outcome. If the exclusion of
trials at high risk of bias did not substantially alter the direction
of effect or the precision of the effect estimates, then we included
data from these trials in the analysis.
4. Imputed values
Had we imputed any values, we would have carried out a sensitiv-
ity analysis to assess the effects of including data from trials where
we used imputed values for ICC in calculating the design effect in
cluster-randomised trials. We will undertake this sensitivity anal-
ysis in future versions of this review where such imputations may
be made.
If substantial differences are noted in the direction or precision of
effect estimates in any of the sensitivity analyses listed above, we
will not pool data from the excluded trials with the other trials
contributing to the outcome, but will present them separately.
5. Fixed-effect and random-effects
We synthesised all data using a random-effects model, however,
we also synthesised data for the primary outcome using a ﬁxed-
effect model to evaluate whether this alters the signiﬁcance of the
results.
6. Economic summary
We undertook a sensitivity analysis taking into account both the
upper and lower conﬁdence intervals for the risk ratios, of the
outcomes of interest, and calculated a saving based on these values
to investigate how far this affects the direction of the estimated
value.
R E S U L T S
Description of studies
For substantive descriptions of studies please see Characteristics
of included studies, Characteristics of excluded studies and
Characteristics of studies awaiting classiﬁcation tables.
Results of the search
Please see Figure 2 for a visual description of the study search
process and study inclusion/exclusion details. Our study search
identiﬁed 501 records; after duplicates were removed, we screened
a total of 409 references. Of these, we excluded 390 based on title
and abstract, with only 19 full-text references requested for full
inspection. Of these, four studies were included.
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Figure 2. Study flow diagram: 2013 study search
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Included studies
1. Length of trials
Studies ranged from six weeks duration of treatment to 22 weeks.
Boyer 1987 and Saletu 1994 both had a washout period of three
weeks and three days respectively, with a treatment duration of
six weeks. Conley 2005 had a four- to six-week open-label lead-in
phase, with a 12-week treatment duration, and Dossenbach 1998
had two treatment phases, one for ’acute’ (six weeks) and one for
’long term’ (22 weeks).
2. Design
All included studies were parallel arm RCTs; only one study had
more than two treatment arms (Conley 2005). No included study
adequately described the randomisation methods used.
3. Participants
All participants had a diagnosis of schizophrenia with eitherDSM-
III (Diagnostic and Statistical Manual, third edition) (Boyer 1987;
Conley 2005; Saletu 1994) or DSM-IV (Diagnostic and Statisti-
cal Manual, fourth edition) (Dossenbach 1998). Participants in-
cluded in Conley 2005 were deﬁned as ’treatment-refractory’, and
participants in Dossenbach 1998 were assessed both in the ’acute’
stage (with results up to six weeks), as well as the long-term treat-
ment (up to 22 weeks).
4. Setting
Three out of the four studies provided details as to trial setting:
Conley 2005 was undertaken in the USA; Dossenbach 1998 was
undertaken in Croatia with a multicentre design; and Saletu 1994
was undertaken in Austria. Boyer 1987 provided no details.
5. Study size
Study sizes ranged from n = 40 (Conley 2005; Saletu 1994) to n
= 62 (Boyer 1987). The total number of included participants in
this review is n = 202.
6. Interventions
6.1 Fluphenazine
The total number of participants receiving ﬂuphenazine was n =
92.Doses of ﬂuphenazine were relatively uniformbetween studies,
with one study permitting a larger dose range (Dossenbach 1998).
Boyer 1987 used a range of 2 mg to 12 mg/day; Conley 2005 used
a mean of 13.2 mg/day; Dossenbach 1998 used a range of 5 mg
to 20 mg/day, with a mean dose of 11.7 mg/day overall in both
the ’acute’ and ’long-term’ phase of the study; Saletu 1994 used a
range of 2 mg to 4 mg/day.
6.2 Amisulpride
Two studies compared amisulpride with ﬂuphenazine; the total
number of participants receiving amisulpride was n = 53. Boyer
1987 used a range of 50 mg to 300 mg/day; and Saletu 1994 used
a range of 50 mg to 100 mg/day.
6.3 Olanzapine
One study compared the olanzapine with ﬂuphenazine; the to-
tal number of participants receiving olanzapine was n = 30.
Dossenbach 1998 used a range of 6mg to 21 mg/day, with a mean
average of 13.6 mg/day in the ’acute’ phase, and 14.8 mg/day in
the ’long-term’ study phase.
6.4 Quetiapine
One study compared the quetiapine with ﬂuphenazine; the total
number of participants receiving quetiapine was n = 12. Conley
2005 used a mean dose of 463.6 mg/day.
6.5 Risperidone
One study compared the risperidone with ﬂuphenazine; the total
number of participants receiving risperidone was n = 13. Conley
2005 used a mean dose of 4.31 mg/day.
7. Outcomes
7.1 General remarks
We did not conduct a meta-analysis as the four included studies
were presented in four different comparisons. Studies were gener-
ally lacking that compared ﬂuphenazine oral with other atypical
antipsychotics, and as a consequence, outcome-reporting between
studies was not consistent. Only two studies provided data for out
primary outcome of ’clinically important response’ (Conley 2005;
Dossenbach 1998).
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7.2 Acceptability and efficacy
Each included study provided data regarding mental and global
state outcomes (widely-accepted rating scales, including the Brief
Psychiatric Rating Scale (BPRS), Positive and Negative Symptom
Scale (PANSS) and Clinical Global Impression (CGI)), however
some of these data were skewed and are presented in an additional
table.
7.3 Adverse events
Adverse events, including anticholinergic effects, central nervous
system effects, gastrointestinal effects and ’others’ were generally
well-reported in the included studies. However data were seriously
lacking for extrapyramidal adverse effects.
7.4 Outcome scales
7.4.1 Global state
i) Clinical Global Impression - CGI (Guy 1976)
This is a rating instrument that enables clinicians to quantify sever-
ity of illness and overall clinical improvement during therapy. A
seven-point scoring system is usually used with low scores indi-
cating decreased severity and/or greater recovery. Three studies
reported data using this scale (Conley 2005; Dossenbach 1998;
Saletu 1994).
7.4.2 Mental state
i) Association for Methodology and Documentation in Psychiatry -
AMDP (Gebhardt 1983)
The AMDP consists of a glossary of psychopathological symp-
toms, as well as rating criteria to assist standardisation in recording.
One included study measured degrees of apathy in participants
using the AMDP manual criteria (Saletu 1994).
ii) Brief Psychiatric Rating Scale - BPRS (Overall 1962)
This scale is used to assess the severity of abnormal mental states.
The original scale has 16 items, but a revised 18-item scale is com-
monly used. Each item is deﬁned on a seven-point scale vary-
ing from ’not present’ to ’extremely severe’, scoring from zero to
six or one to seven. Scores can range from zero to 108 or 18 to
126, respectively.High scores indicatemore severe symptoms. The
BPRS-positive cluster comprises four items, which are conceptual
disorganisation, suspiciousness, hallucinatory behaviour and un-
usual thought content. The BPRS-negative cluster comprises only
three items, which are emotional withdrawal, motor retardation,
and blunted affect. Three studies reported data using this scale
(Boyer 1987; Conley 2005; Dossenbach 1998).
iii) Hamilton Anxiety Scale - HAMA (Maier 1988)
HAMA is a rating scale developed to quantify the severity of anxi-
ety symptomatology and consists of 14 items, each deﬁned by a se-
ries of symptoms. Each item is rated on a ﬁve-point scale, ranging
from zero (= not present) to four (= severe). One study reported
continuous data using this scale (Dossenbach 1998).
iv) Positive and Negative Symptom Scale - PANSS (Kay 1987)
The positive and negative syndrome scale was originated as a
method for evaluating positive, negative and other symptom di-
mensions in schizophrenia. The scale has 30 items, and each item
can be rated on a seven-point scoring system varying from one
(absent) to seven (extreme). This scale can be divided into three
subscales for measuring the severity of general psychopathology,
positive symptoms (PANSS-P) and negative symptoms (PANSS-
N). A low score indicates low levels of symptoms. One study pro-
vided data using this scale (Dossenbach 1998).
v) Scale for Assessment of Negative Symptoms - SANS (Andreasen
1982)
The SANS measures the incidence and severity of negative symp-
toms using a 25-item scale, using a six-point scoring system, where
zero = better to ﬁve = worse, where a higher score equals a more
severe experience of negative symptoms. One study reported data
using this scale (Saletu 1994).
7.4.3 Satisfaction with treatment
i) Drug Attitude Inventory - DAI (Hogan 1983)
The DAI is a self-administered rating scale designed to gain un-
derstanding of patient-use and personal experiences of using psy-
chiatric medication. There are 30 items, which are rated as either
’true’ or ’false’ by users, including statements such as ’medication
is a slow-acting poison’, or ’I can’t concentrate on anything when
I’m on medication’. One study provided continuous data using
this scale (Dossenbach 1998).
7.4.4 Adverse events
i) Assessment of Involuntary Movements Scale - AIMS (Guy 1976a)
This scale measures the examination of involuntary movements
(tardive dyskinesia) consisting of 12 items scored from zero = none
to four = severe, quantifying the severity of tardive dyskinesia. This
scale used in short-term trials may also help to assess Parkinsonian
symptoms such as tremor. One study reported continuous data
using this scale (Dossenbach 1998).
ii) Hillside Akathisia Scale - HAS (Fleischhacker 1989)
The HAS was used to measure akathisia; the subjective subscale
has two subjective and three objective items for which anchored
rating points are provided. The subjective items take into account
a patient’s sensation of restlessness and urge to move, and the
objective items assess physical signs of akathisia present in the
head, trunk, hands, arms, feet and legs. There are a total of ﬁve
items, which are measured on a ﬁve-point scoring system from
zero = absent to four = present and not controllable. One study
provided data using this scale (Dossenbach 1998).
iii) Leeds Sleep Evaluation Questionnaire - LSEQ (Parrott 1980)
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The LSEQ is a 10-item, self-rating measurement designed to as-
sess changes in sleep quality over the course of psychopharmaco-
logical treatment. Four domains are rated, including ’ease of ini-
tiating sleep’, ’quality of sleep’, ’ease of waking’ and ’behaviour
following wakefulness’. One study reported data using this scale
(Dossenbach 1998).
iv) Simpson-Angus Scale - SAS (Simpson 1970)
The SAS measures drug-related extrapyramidal symptoms; it is a
10-item rating scale, with a score range of zero ( = not present) to
40 ( = severe); it includes items such as gait, rigidity, tremor and
salivation. One study reported data using this scale (Dossenbach
1998).
7.5 Missing outcomes
The four included studies failed to report several of our pre-spec-
iﬁed secondary outcomes of interest, including economic out-
comes, quality of life outcomes, service-use and hospitalisation
outcomes, relapse, and general function (such as social skills, em-
ployability). These are particularly patient-important outcomes
that have been overlooked, and would add to the body of evidence
regarding acceptability of treatment.
Excluded studies
We excluded ﬁve studies. Three, or perhaps two, studies com-
pared amisulpride with placebo, haloperidol, or at different doses
(Boyer 1986; Boyer 1987a; Boyer 1996). Pickar 1992 was not a
randomised study and Ravanic 1996 provided no useable data.
Studies awaiting assessment
One study awaits assessment as only a conference abstract is avail-
able with no usable data available; the full report is required
(Djukic-Dejanovic 2002).
Ongoing studies
We identiﬁed no ongoing studies.
Risk of bias in included studies
For a graphical overview of ’Risk of bias’ assessments in included
studies, see Figure 3; Figure 4.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 4. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
None of the included studies provided adequate details as to ran-
domisation methods and were all rated as an ’unclear’ risk of bias.
Conley 2005 stated that randomisation was performed by the dis-
pensing pharmacy; Dossenbach 1998 stated that randomisation
was undertaken in a 1:1 ratio; while Boyer 1987 and Saletu 1994
simply stated that participants were ’randomly allocated’, with no
further details.
Blinding
Again, none of the included studies provided adequate details as
to blinding methods and were all rated as an ’unclear’ risk of bias,
with all studies only stating that studies were double-blinded.
Incomplete outcome data
Three included studies were rated as a ’high’ risk of bias for at-
trition; in Boyer 1987, not all participants completed ratings for
various BPRS components, and it was unclear whether last obser-
vation carried forward (LOCF) was used. Forty participants were
randomised in Conley 2005, however data for n = 2 were ’lost’,
and only n = 38 (out of n = 40 randomised) were presented in
the data and analysis. In Dossenbach 1998, all participants were
included in the safety analysis. However for efﬁcacy n = 5 were
excluded because they did not meet inclusion criteria for BPRS or
CGI.
Selective reporting
Three studies were rated as a ’high’ risk of bias for selective report-
ing; Boyer 1987, Conley 2005 and Saletu 1994 did not report all
stated outcome measures, particularly relating to continuous data
with means and standard deviations not transparently reported.
Dossenbach 1998 was rated as a ’low’ risk due to higher standards
of reporting outcome data.
Other potential sources of bias
Two studies were rated as ’unclear’ for other bias (Boyer 1987;
Conley 2005), while the other two studies rated as ’high’
(Dossenbach 1998; Saletu 1994). We did not detect any obvi-
ous other sources of bias with Boyer 1987; study medications
were supplied by Janssen Pharmaceutica and Astra-Zeneca Phar-
maceuticals in Conley 2005. For the two studies rated as a ’high’
risk (Dossenbach 1998; Saletu 1994), both were sponsored by
the pharmaceutical industry, including Eli Lilly and Company
(Dossenbach 1998) and Synthelabo Recherche/Laboratoires De-
lagrange (Bagneux, France) (Saletu 1994).
Effects of interventions
See: Summary of findings for the main comparison
FLUPHENAZINE (ORAL) compared to AMISULPRIDE for
schizophrenia; Summary of findings 2 FLUPHENAZINE
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(ORAL) compared to RISPERIDONE for schizophrenia;
Summary of findings 3 FLUPHENAZINE (ORAL) compared
to QUETIAPINE for schizophrenia; Summary of findings 4
FLUPHENAZINE (ORAL) compared to OLANZAPINE for
schizophrenia
COMPARISON 1: FLUPHENAZINE (ORAL) versus
AMISULPRIDE
1.1 Global state: 1. Average endpoint score of CGI scales
(high = poor)
1.1.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 36) (Saletu
1994). There was no signiﬁcant difference between ﬂuphenazine
(oral) and amisulpride (mean difference (MD) -0.34 95% conﬁ-
dence interval (CI) -0.90 to 0.22, Analysis 1.1).
1.2 Mental state: 2a. Average endpoint score of various
scales (high = poor)
1.2.1 BPRS - anxiety/depression subscale score - short term
(up to 12 weeks)
In this subgroup we only found one relevant trial (n = 57)
(Boyer 1987). We found evidence of a clear difference between
’ﬂuphenazine (oral)’ and ’amisulpride’ within this subgroup (MD
2.60 95% CI 1.40 to 3.80, Analysis 1.2).
1.2.2 BPRS total score - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 57) (Boyer
1987). There was not a clear difference between ’ﬂuphenazine
(oral)’ and ’amisulpride’ within this subgroup (MD 5.10 95% CI
-2.35 to 12.55, Analysis 1.2).
1.2.3 SANS total score - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 36) (Saletu
1994). There was a statistically signiﬁcant difference (P = 0.03)
favouring ﬂuphenazine (oral) over amisulpride (MD -9.49 95%
CI -17.88 to -1.10, Analysis 1.2).
1.3 Mental state: 2b. Average endpoint score of AMDP scale
(high = poor)
1.3.1 short term (up to 12 weeks)
Data for this outcome are skewed and are best inspected by viewing
Analysis 1.3.
1.4 Adverse effects: 1. Extrapyramidal side effects
1.4.1 concomitant anticholinergic medication - short term
(up to 12 weeks)
In this subgroup we only found one relevant trial (n = 36) (Saletu
1994). There was a statistically signiﬁcant difference (P = 0.04)
favouring amisulpride over ﬂuphenazine (oral) (risk ratio (RR)
7.82 95% CI 1.07 to 57.26, Analysis 1.4).
1.5 Leaving the study early
1.5.1 any reason
In this subgroup we found two trials (n = 98). There was no
signiﬁcant difference between the two treatment groups (RR 1.19
95% CI 0.63 to 2.28, Analysis 1.5)
1.5.2 adverse effects - short term (up to 12 weeks)
In this subgroup we found two trials (n = 98). There was no
signiﬁcant difference between ﬂuphenazine (oral) and amisulpride
(RR 1.88 95% CI 0.24 to 14.68, Analysis 1.5).
1.5.1 inefficacy - short term (up to 12 weeks)
In this subgroup we found two trials (n = 98). There was no
signiﬁcant difference between ﬂuphenazine (oral) and amisulpride
(RR 1.82 95% CI 0.68 to 4.84, Analysis 1.5).
1.5.3 productive symptoms - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 36) (Saletu
1994). There was no signiﬁcant difference between ﬂuphenazine
(oral) and amisulpride (RR 0.37 95% CI 0.04 to 3.25, Analysis
1.5).
COMPARISON 2: FLUPHENAZINE (ORAL) versus
RISPERIDONE
2.1 Clinically important response (defined by study)
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2.1.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 26) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 0.67 95% CI 0.13 to 3.35, Analysis
2.1).
2.2 Global state: 1. Average endpoint score of CGI scales
(high = poor)
2.2.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 26) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (MD 0.07 95% CI -0.77 to 0.91, Analysis
2.2).
2.3 Mental state: 2a. Average endpoint scores (BPRS, high =
poor)
2.3.1 BPRS endpoint total scale score - short term (up to 12
weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (MD -1.98 95%CI -12.96 to 9.00, Analysis
2.3).
2.3.2 BPRS positive subscale score - short term (up to 12
weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (MD -0.15 95% CI -4.22 to 3.92, Analysis
2.3).
2.3.3 BPRS negative subscale score - short term (up to 12
weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (MD -1.54 95% CI -3.94 to 0.86, Analysis
2.3).
2.3.4 BPRS hostile subscale score - short term (up to 12
weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (MD 0.92 95% CI -2.21 to 4.05, Analysis
2.3).
2.4 Mental state: 2b. Average endpoint score of various
scales (high = poor) - short term (up to 12 weeks) (skewed
data)
2.4.1 BPRS anxiety/depression subscale score
Data for this outcome are skewed and are best inspected by viewing
Analysis 2.4.
2.4.2 BPRS activation subscale score
Data for this outcome are skewed and are best inspected by viewing
Analysis 2.4.
2.5 Adverse effects: 1. Anticholinergic effect
2.5.1 blurred vision - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 1.08 95% CI 0.18 to 6.53, Analysis
2.5).
2.5.2 dry mouth - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 1.08 95% CI 0.18 to 6.53, Analysis
2.5).
2.5.3 urinary hesitancy - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 5.38 95% CI 0.28 to 101.96, Analysis
2.5).
2.6 Adverse effects: 2. Central nervous system
2.6.1 anxiety - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 0.54 95% CI 0.06 to 5.24, Analysis
2.6).
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2.6.2 headache - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 0.77 95% CI 0.33 to 1.79, Analysis
2.6).
2.6.3 lethargy - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 0.81 95% CI 0.23 to 2.91, Analysis
2.6).
2.6.4 insomnia - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 1.81 95% CI 0.55 to 5.98, Analysis
2.6).
2.6.5 somnolence - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 0.87 95% CI 0.30 to 2.49, Analysis
2.6).
2.7 Adverse effects: 3. Gastrointestinal
2.7.1 constipation - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 9.69 95% CI 0.58 to 163.02, Analysis
2.7).
2.7.2 diarrhoea - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 0.22 95% CI 0.01 to 4.08, Analysis
2.7).
2.7.3 dyspepsia - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 3.25 95% CI 0.39 to 27.15, Analysis
2.7).
2.7.4 nausea/vomiting - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 0.72 95% CI 0.14 to 3.61, Analysis
2.7).
2.8 Adverse effects: 4. Other adverse events
2.8.1 urinary frequency - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 0.36 95% CI 0.02 to 8.05, Analysis
2.8).
2.8.2 orthostasis - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 0.43 95% CI 0.10 to 1.83, Analysis
2.8).
2.8.3 increased appetite - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 0.72 95% CI 0.14 to 3.61, Analysis
2.8).
2.8.4 dizziness - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and risperidone (RR 0.36 95% CI 0.04 to 3.02, Analysis
2.8).
2.9 Adverse effects: 5. Average endpoint weight loss (kg)
(skewed data)
2.9.1 short term (up to 12 weeks)
Data for this outcome are skewed and are best inspected by viewing
Analysis 2.9
2.10 Leaving the study early
2.10.1 inefficacy - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
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(oral) and risperidone (RR 1.08 95% CI 0.08 to 15.46, Analysis
2.10).
COMPARISON 3: FLUPHENAZINE (ORAL) versus
QUETIAPINE
3.1 Clinically important response (defined by study)
3.1.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 0.62 95% CI 0.12 to 3.07, Analysis
3.1).
3.2 Global state: 1. CGI: Average endpoint CGI-SI (high =
poor)
3.2.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (MD -0.03 95% CI -0.92 to 0.86, Analysis
3.2).
3.3 Mental state: 2a. General - average endpoint score
(BPRS total, high = poor)
3.3.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (MD -1.98 95% CI -12.96 to 9.00, Analysis
3.3).
3.4 Mental state: 2b. Positive symptoms - average endpoint
score (BPRS positive sub-score, high = poor)
3.4.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was a statistically signiﬁcant difference (P = 0.0002)
favouring ﬂuphenazine (oral) over quetiapine (MD -13.61 95%
CI -20.77 to -6.45, Analysis 3.4).
3.5 Mental state: 2c. Negative symptoms - average endpoint
score (BPRS negative sub-score, high = poor)
3.5.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (MD -0.11 95% CI -2.27 to 2.05, Analysis
3.5).
3.6 Mental state: 2d. Anxiety/depression symptoms -
average endpoint score (BPRS anxiety/depression sub-score,
high score = poor)
3.6.1 short term (up to 12 weeks)
Data for this outcome are skewed and are best inspected by viewing
Analysis 3.6.
3.7 Mental state: 2e. Hostility symptoms - average endpoint
score (BPRS hostility sub-score, high = poor)
3.7.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (MD 0.79 95% CI -2.45 to 4.03, Analysis
3.7).
3.8 Mental state: 2f. Activation symptoms - average
endpoint score (BPRS activation sub-score, high = poor)
3.8.1 short term (up to 12 weeks)
Data for this outcome are skewed and are best inspected by viewing
Analysis 3.8.
3.9 Adverse effects: 1. Anticholinergic effect
3.9.1 dry mouth - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 1.00 95% CI 0.17 to 5.98, Analysis
3.9).
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3.9.2 blurred vision - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 1.00 95% CI 0.17 to 5.98, Analysis
3.9).
3.9.3 urinary hesitancy - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 1.00 95% CI 0.17 to 5.98, Analysis
3.9).
3.10 Adverse effects: 2. Central nervous system
3.10.1 anxiety - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 1.00 95% CI 0.07 to 14.21, Analysis
3.10).
3.10.2 headache - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 1.00 95% CI 0.39 to 2.58, Analysis
3.10).
3.10.3 insomnia - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 1.67 95% CI 0.51 to 5.46, Analysis
3.10).
3.10.4 lethargy - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 1.50 95% CI 0.30 to 7.43, Analysis
3.10).
3.10.5 somnolence - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 1.33 95% CI 0.38 to 4.72, Analysis
3.10).
3.11 Adverse effects: 3. Gastrointerstinal adverse effects
3.11.1 constipation - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 1.00 95% CI 0.32 to 3.10, Analysis
3.11).
3.11.2 diarrhoea - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 0.20 95% CI 0.01 to 3.77, Analysis
3.11).
3.11.3 dyspepsia - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 3.00 95% CI 0.36 to 24.92, Analysis
3.11).
3.11.4 nausea/ vomiting - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 2.00 95% CI 0.21 to 19.23, Analysis
3.11).
3.12 Adverse effects: 4a. Other adverse events
3.12.1 dizziness - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 1.00 95% CI 0.07 to 14.21, Analysis
3.12).
3.12.2 increased appetite - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 0.67 95% CI 0.13 to 3.30, Analysis
3.12).
3.12.3 orthostasis - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 2.00 95% CI 0.21 to 19.23, Analysis
3.12).
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3.12.4 urinary frequency - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 24) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 0.33 95% CI 0.01 to 7.45, Analysis
3.12).
3.13 Adverse effects: 4b. Other - average endpoint weight
loss (average weight in kg) (skewed)
3.13.1 short term (up to 12 weeks)
Data for this outcome are skewed and are best inspected by viewing
Analysis 3.13.
3.14 Leaving the study early
3.14.1 inefficacy - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 0.46 95% CI 0.05 to 4.46, Analysis
3.14).
3.14.2 adverse effects - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 25) (Conley
2005). There was no signiﬁcant difference between ﬂuphenazine
(oral) and quetiapine (RR 0.19 95% CI 0.01 to 3.52, Analysis
3.14).
COMPARISON 4: FLUPHENAZINE (ORAL) versus
OLANZAPINE
4.1 Clinically important response (defined by author)
4.1.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (RR1.33 95%CI 0.86 to 2.07,
Analysis 4.1).
4.1.2 medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (RR1.60 95%CI 0.87 to 2.94,
Analysis 4.1).
4.2 Global state: 1. CGI: Average change CGI-SI (high =
poor)
4.2.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 55)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.05) favouring olanzapine over ﬂuphenazine (oral) (MD
0.70 95% CI -0.01 to 1.41, Analysis 4.2).
4.2.2 medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 55)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.02) favouring olanzapine over ﬂuphenazine (oral) (MD
0.90 95% CI 0.13 to 1.67, Analysis 4.2).
4.3 Mental state: 2a. General - average change score (BPRS
total, high = poor)
4.3.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 54)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD 7.10 95% CI -1.15 to
15.35, Analysis 4.3).
4.3.2 medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 54)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.05) favouring olanzapine over ﬂuphenazine (oral) (MD
9.30 95% CI 0.10 to 18.50, Analysis 4.3).
4.4 Mental state: 2b. General - average change score
(PANSS total, high = poor)
4.4.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 54)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD 12.00 95% CI -2.03 to
26.03, Analysis 4.4).
4.4.2 medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 54)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.04) favouring olanzapine over ﬂuphenazine (oral) (MD
16.20 95% CI 0.41 to 31.99, Analysis 4.4).
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4.5 Mental state: 2c. Positive symptoms - average change
score (BPRS positive sub-score, high = poor)
4.5.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 55)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD 2.30 95% CI -0.67 to
5.27, Analysis 4.5).
4.5.2 medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 55)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD 2.90 95% CI -0.29 to
6.09, Analysis 4.5).
4.6 Mental state: 2d. Positive symptoms - average endpoint
score (PANSS positive sub-score, high = poor)
4.6.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 55)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.03) favouring ﬂuphenazine (oral) over olanzapine (MD -
5.10 95% CI -9.68 to -0.52, Analysis 4.6).
4.6.2 medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 55)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.03) favouring ﬂuphenazine (oral) over olanzapine (MD -
5.10 95% CI -9.82 to -0.38, Analysis 4.6).
4.7 Mental state: 2e. Negative symptoms - average change
score (BPRS negative sub-score, high = poor)
4.7.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 55)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD 1.20 95% CI -0.47 to
2.87, Analysis 4.7).
4.7.2 medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 55)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD 1.70 95% CI -0.31 to
3.71, Analysis 4.7).
4.8 Mental state: 2f. Negative symptoms - average change
score (PANSS negative sub-score, high = poor)
4.8.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 54)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD 2.40 95% CI -0.96 to
5.76, Analysis 4.8).
4.8.2 medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 54)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD 3.00 95% CI -1.22 to
7.22, Analysis 4.8).
4.9 Mental state: 2g. General psychopathology - average
change score (PANSS general psychopathology sub-score,
high = poor)
4.9.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 54)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD 6.20 95% CI -0.90 to
13.30, Analysis 4.9).
4.9.2 medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 54)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.04) favouring olanzapine over ﬂuphenazine (oral) (MD
8.20 95% CI 0.43 to 15.97, Analysis 4.9).
4.10 Mental state: 2h. Anxiety - average change score
(HAMA, high = poor)
4.10.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 54)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.05) favouring olanzapine over ﬂuphenazine (oral) (MD
4.00 95% CI 0.08 to 7.92, Analysis 4.10).
4.10.2 medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 59)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.05) favouring olanzapine over ﬂuphenazine (oral) (MD
6.00 95% CI -0.12 to 12.12, Analysis 4.10).
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4.11 Satisfaction with treatment: 1. Average change score
(DAI, low = poor)
4.11.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 52)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD -1.20 95% CI -2.44 to
0.04, Analysis 4.11).
4.11.2 medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 52)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.03) favouring olanzapine over between ﬂuphenazine (oral)
(MD -1.10 95% CI -2.08 to -0.12, Analysis 4.11).
4.12 Adverse effects: 1. General
4.12.1 at least one adverse effect - medium term (13 to 26
weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.04) favouring olanzapine over ﬂuphenazine (oral) (RR 1.53
95% CI 1.02 to 2.31, Analysis 4.12).
4.13 Adverse effects: 2. Anticholinergic effect
4.13.1 concomitant anticholinergic medication - average
endpoint dosage (mg/day) - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.001) favouring olanzapine over between ﬂuphenazine (oral)
(MD 0.89 95% CI 0.35 to 1.43, Analysis 4.13).
4.13.2 concomitant anticholinergic medication - average
endpoint dosage (mg/day) - medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.008) favouring olanzapine over between ﬂuphenazine (oral)
(MD 1.08 95% CI 0.28 to 1.88, Analysis 4.13).
4.14 Adverse effects: 3a. Central nervous system
4.14.1 insomnia - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (RR 13.00 95% CI 0.76 to
220.96, Analysis 4.14).
4.15 Adverse effects: 3b. CNS (LSEQ, low = poor)
4.15.1 awakening from sleep average endpoint score - short
term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 53)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD -2.70 95% CI -10.18 to
4.78, Analysis 4.15).
4.15.2 behaviour following wakefulness average endpoint
score - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 53)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD -6.60 95% CI -13.92 to
0.72, Analysis 4.15).
4.15.3 getting to sleep average endpoint score - short term
(up to 12 weeks)
In this subgroup we only found one relevant trial (n = 53)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD -4.40 95% CI -14.18 to
5.38, Analysis 4.15).
4.15.4 sleep quality - average endpoint score - short term (up
to 12 weeks)
In this subgroup we only found one relevant trial (n = 53)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD -6.10 95% CI -15.97 to
3.77, Analysis 4.15).
4.16 Adverse effects: 4a. Extrapyramidal effects
4.16.1 akathisia - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (RR 3.00 95% CI 0.90 to
10.01, Analysis 4.16).
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4.16.2 hypertonia - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (RR 3.00 95% CI 0.33 to
27.23, Analysis 4.16).
4.16.3 tremor - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (RR1.00 95%CI 0.22 to 4.56,
Analysis 4.16).
4.17 Adverse effects: 4b. Extrapyramidal effects - average
change score (SAS, high = poor)
4.17.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.001) favouring olanzapine over ﬂuphenazine (oral) (MD
4.20 95% CI 1.68 to 6.72, Analysis 4.17).
4.17.2 medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.008) favouring olanzapine over ﬂuphenazine (oral) (MD
4.00 95% CI 1.02 to 6.98, Analysis 4.17).
4.18 Adverse effects: 4c. Extrapyramidal effects - average
change score (HAS, high = poor)
4.18.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 59)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.02) favouring olanzapine over ﬂuphenazine (oral) (MD
6.60 95% CI 0.88 to 12.32, Analysis 4.18).
4.18.2 medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 59)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.05) favouring olanzapine over ﬂuphenazine (oral) (MD
6.00 95% CI -0.12 to 12.12, Analysis 4.18).
4.19 Adverse effects: 4d. Extrapyramidal effects - average
change score (AIMS, high = poor)
4.19.1 short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD 1.10 95% CI -0.11 to
2.31, Analysis 4.19).
4.19.2 medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (MD 1.10 95% CI -0.45 to
2.65, Analysis 4.19).
4.20 Adverse effects: 5. Other adverse events
4.20.1 weight gain - medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (RR0.09 95%CI 0.01 to 1.57,
Analysis 4.20).
4.21 Adverse effects: 5b. Other adverse events
4.21.1 concomitant anxiolytics medication average dosage
(mg/day) - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.05) favouring olanzapine over ﬂuphenazine (oral) (MD
4.65 95% CI 0.07 to 9.23, Analysis 4.21).
4.21.2 concomitant anxiolytics medication - average dosage
(mg/day)- medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.03) favouring olanzapine over ﬂuphenazine (oral) (MD
6.10 95% CI 0.63 to 11.57, Analysis 4.21).
4.21.3 effects on physiology - supine systolic blood pressure
(average in mmHg) - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.02) favouring ﬂuphenazine (oral) over olanzapine (MD -
10.00 95% CI -18.11 to -1.89, Analysis 4.21).
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4.21.4 effects on physiology - supine systolic blood pressure
(average in mmHg) - medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was a statistically signiﬁcant difference
(P = 0.02) favouring ﬂuphenazine (oral) over olanzapine (MD -
10.00 95% CI -18.11 to -1.89, Analysis 4.21).
4.22 Adverse effects: 5c. Other (skewed)
4.22.1 weight gain (average weight in kg) - short term (up to
12 weeks)
Data for this outcome are skewed and are best inspected by viewing
Analysis 4.22.
4.22.2 weight gain (average weight in kg) - medium term (13
to 26 weeks)
Data for this outcome are skewed and are best inspected by viewing
Analysis 4.22.
4.23 Leaving the study early
4.23.1 inefficacy - short term (up to 12 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (RR 3.00 95% CI 0.33 to
27.23, Analysis 4.23).
4.23.2 adverse effects - medium term (13 to 26 weeks)
In this subgroup we only found one relevant trial (n = 60)
(Dossenbach 1998). There was no signiﬁcant difference between
ﬂuphenazine (oral) and olanzapine (RR 9.00 95% CI 0.51 to
160.17, Analysis 4.23).
5. SENSITIVITY ANALYSIS
5.1 Implication of randomisation
None of the included studies provided adequate details as to ran-
domisation methods; furthermore, meta-analysis was not possible
for our primary outcome, therefore the removal of studies with an
inadequate description of randomisation left us with no data to
compare.
5.2 Assumptions for lost binary data
Due to the relatively small loss to follow-up between studies, there
was no difference in the estimate of effect of our primary outcome
when we compared completer-only data with intention-to-treat
analysis. Evenwhenwe assumed the extreme of each person leaving
having a good outcome - this changed the ﬁndings by degree but
not by direction and in no case changed the equivocal statistical
signiﬁcance of the results (Table 2).
5.3 Risk of bias
Each included study was rated as a ’high’ risk of bias across at least
one of the domains; again, meta-analysis was not possible for our
primary outcome, therefore the removal of studies rated as a ’high’
risk left us with no data to compare.
5.4 Imputed values
We did not include any cluster-randomised studies and therefore
did not impute any ICC values.
5.5 Fixed-effect and random-effects
Since meta-analysis was not possible, there was no difference in
the estimate of effect when using a ﬁxed-effect model as opposed
to a random-effects model.
6. Economic consideration of results
This review is one of several selected for economic consideration
of ﬁndings. As yet, this has not been completed but should be
available for next update.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
FLUPHENAZINE (ORAL) compared to RISPERIDONE for schizophrenia
Patient or population: pat ients with schizophrenia
Settings: USA
Intervention: FLUPHENAZINE (ORAL)
Comparison: RISPERIDONE
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
RISPERIDONE FLUPHENAZINE
(ORAL)
Clinically important re-
sponse (defined by
study) - short term (up
to 12 weeks)
decreased rate of BPRS
score < 20%
Follow-up: 12 weeks
231 per 10001 155 per 1000
(30 to 773)
RR 0.67
(0.13 to 3.35)
26
(1 study)
⊕©©©
very low2,3,4
Relapse (long term) -
not reported
See comment See comment Not est imable - See comment No study reported this
outcome
Clini-
cally important change
in life skills (long term)
- not reported
See comment See comment Not est imable - See comment No study reported this
outcome
Quality of life (long
term) - not reported
See comment See comment Not est imable - See comment No study reported this
outcome
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Adverse effects: Ex-
trapyramidal effects -
short/ medium term (up
to 12 weeks) - not re-
ported
See comment See comment Not est imable - See comment No study reported this
outcome
Leaving the study early
- inefficacy short term
(up to 12 weeks)
Follow-up: 12 weeks
77 per 10001 83 per 1000
(6 to 1000)
RR 1.08
(0.08 to 15.46)
25
(1 study)
⊕©©©
very low2,3,4
Cost-effective-
ness (long term) - not
reported
See comment See comment Not est imable - See comment No study reported this
outcome <BR/ >
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Control risk: mean baseline risk presented for single included study.
2 Risk of bias: rated ’serious’ - randomisat ion methods unclear; rated ’high’ for attrit ion bias, with data for some included
part icipants ’lost ’; only one small study included (Conley 2005, n = 40).
3 Indirectness: rated ’serious’ - only one included study provided data, which had three treatment arms (f luphenazine versus
risperidone versus quet iapine).
4 Imprecision: rated ’very serious’ - few part icipants, few events, leading to uncertainty in the precision of est imate of ef fect.
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FLUPHENAZINE (ORAL) compared to QUETIAPINE for schizophrenia
Patient or population: pat ients with schizophrenia
Settings: USA
Intervention: FLUPHENAZINE (ORAL)
Comparison: QUETIAPINE
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
QUETIAPINE FLUPHENAZINE
(ORAL)
Clinically important re-
sponse (defined by
study) - short term (up
to 12 weeks)
decreased rate of BPRS
score < 20%
Follow-up: 12 weeks
250 per 10001 155 per 1000
(30 to 767)
RR 0.62
(0.12 to 3.07)
25
(1 study)
⊕©©©
very low2,3,4
Relapse (long term) See comment See comment Not est imable - See comment
Clini-
cally important change
in life skills (long term)
See comment See comment Not est imable - See comment
Quality of life (long
term)
See comment See comment Not est imable - See comment
Adverse effects: Ex-
trapyramidal effects -
short/ medium term (up
to 12 weeks)
See comment See comment Not est imable - See comment
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Leaving the study early
- inefficacy - short term
(up to 12 weeks)
Follow-up: 12 weeks
167 per 10001 77 per 1000
(8 to 743)
RR 0.46
(0.05 to 4.46)
25
(1 study)
⊕©©©
very low2,3,4
Cost-effectiveness
(long term)
See comment See comment Not est imable - See comment
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Control risk: mean baseline risk presented for single included study.
2 Risk of bias: rated ’serious’ - randomisat ion methods unclear; rated ’high’ for attrit ion bias, with data for some included
part icipants ’lost ’; only one small study included (Conley 2005, n = 40).
3 Indirectness: rated ’serious’ - only one included study provided data, which had three treatment arms (f luphenazine versus
risperidone versus quet iapine).
4 Imprecision: rated ’very serious’ - few part icipants, few events, leading to uncertainty in the precision of est imate of ef fect.
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FLUPHENAZINE (ORAL) compared to OLANZAPINE for schizophrenia
Patient or population: pat ients with schizophrenia
Settings: mult icentre, Croat ia
Intervention: FLUPHENAZINE (ORAL)
Comparison: OLANZAPINE
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
OLANZAPINE FLUPHENAZINE
(ORAL)
Clinically important re-
sponse (defined by
study) - short term (up
to 12 weeks)
decreased rate of
PANSS score < 40%, de-
creased rate of BPRS
score < 40%
Follow-up: 22 weeks
500 per 10001 665 per 1000
(430 to 1000)
RR 1.33
(0.86 to 2.07)
60
(1 study)
⊕©©©
very low2,3
Relapse (long term) -
not reported
See comment See comment Not est imable - See comment No study reported this
outcome
Clini-
cally important change
in life skills (long term)
- not reported
See comment See comment Not est imable - See comment No study reported this
outcome
Quality of life (long
term) - not reported
See comment See comment Not est imable - See comment No study reported this
outcome
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Adverse effects: Ex-
trapyramidal effects -
akathisia - short term
(up to 12 weeks)
Follow-up: 22 weeks
100 per 10001 300 per 1000
(90 to 1000)
RR 3.00
(0.90 to 10.01)
60
(1 study)
⊕©©©
very low2,3
Leaving the study
early: inefficacy - short
term (up to 12 weeks)
Follow-up: 22 weeks
33 per 10001 100 per 1000
(11 to 908)
RR 3.00
(0.33 to 27.23)
60
(1 study)
⊕©©©
very low2,3
Cost-effective-
ness (long term) - not
reported
See comment See comment Not est imable - See comment No study reported this
outcome
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Control risk: mean baseline risk presented for single included study.
2 Risk of bias: rated ’serious’ - randomisat ion methods not adequately described; f ive part icipants excluded f rom analysis;
sponsored by pharmaceut ical company.
3 Imprecision: rated ’very serious’ - few part icipants, few events, leading to uncertainty in the precision of est imate of ef fect
(Dossenbach 1998, n = 60).
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D I S C U S S I O N
Summary of main results
1. FLUPHENAZINE (ORAL) versus AMISULPRIDE
1.1 Global state/mental state
Only one small study reported data the global state of partici-
pants in the short term (12 weeks). This showed no difference
between ﬂuphenazine and amisulpride. No trials provided longer-
term data. No trials recorded relapse data. Another small study re-
ported no clear difference between amisulpride and ﬂuphenazine
in the short term using the Brief Psychiatric Rating Scale (BPRS)
(Analysis 1.2). The favourable outcome for negative symptoms
reported by Saletu 1994 is, as always, of interest, but is only based
on a short trial involving 36 people.We found no evidence that for
these key outcomes there is any difference between ﬂuphenazine
and the newer drug - but all data are weak.
1.2 Adverse events
Less of the 19 allocated amisulpride in Saletu 1994 needed con-
comitant use of anticholinergic medication - a proxy measure of
extrapyramidal symptoms. This would support most clinicians’
experiences of ﬂuphenazine having a high propensity to induce ex-
trapyramidal side effects (EPSEs). There is signiﬁcant concern in
reporting bias with this small, drug company-funded study - and
data on adverse events (the Webster Scale and Adverse Experience
Scale) were not reported at all. Newer drugs are often marketed
on having different and less problematic adverse effects than the
old medications - so it is odd that there is not more conﬁdence
and openness in reporting.
1.3 Leaving the study early
One study found no signiﬁcant difference for this outcome be-
tween the compounds.
2. FLUPHENAZINE (ORAL) versus RISPERIDONE
2.1 Global state/mental state
Only one study (n = 26) provided data on global state showing no
difference between the compounds in the short term. There were
no data on relapse. The same study did not show any signiﬁcant
difference between ﬂuphenazine or risperidone on various scales of
mental state response in the short term. This does seem to reﬂect
the situation with amisulpride. No clear difference between the
old and the new drug has been demonstrated.
2.2 Adverse effects
The same study found no difference between the compounds on
a large number of individual adverse events. There is evidence
that there is greater short-term weight gain with risperidone than
ﬂuphenazine. However, there is signiﬁcant concern in the report-
ing of bias in this small, pharmaceutical company-funded study -
data from the Simpson Angus Scale (SAS), the Barnes Akathisia
Scale (BAS), and the Assessment of Involuntary Movements Scale
(AIMS), Sexual Function: Changes in Sexual Function Question-
naire (CSFQ) and the Prolactin-Related Adverse Event Question-
naire (PRAEQ) were not reported. This is concerning as risperi-
done is associated with EPSEs and hyperprolactinaemia and, as
with amisulpride, the reporting biases would tend to favour the
newer drug.
2.3 Leaving the study early
The same study found no signiﬁcant difference between the com-
pounds for this outcome in the short term.
3. FLUPHENAZINE (ORAL) versus QUETIAPINE
3.1 Clinically important response (defined by study)/global
state/mental state
Conley 2005 (n=25) foundnodifference between the compounds
in the short term in terms of ’clinically important response’ and
global state. For one measure on mental state, the same small short
study found a difference favouring ﬂuphenazine over quetiapine
on the positive symptoms sub-score (Analysis 3.4). There were no
demonstrated differences on the negative symptoms sub-score. So,
in keeping with the other comparisons, tiny studies do not ﬁnd
convincing clinical differences between the old and the new drug.
3.2 Adverse effects
Again, as will the comparisons with other newer drugs, the same
small study found no difference between the compounds on a large
number of individual adverse events and reporting bias was con-
siderable. If anything this reporting bias would have been favour-
ing the newer and more expensive drug.
3.3 Leaving the study early
Conley 2005 found no difference between the compounds in the
short term.
4. FLUPHENAZINE (ORAL) versus OLANZAPINE
4.1 Clinically important response (defined by study)/global
state/mental state
Dossenbach 1998 (n = 60) found no difference between the com-
pounds in the short term in terms of ’clinically important response’
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in the short to mid term. The same study found no differences
between compounds in the short term (average change on Cog-
nitive Global Impression (CGI)), but a difference favoured olan-
zapine in the mid term (MD 0.9 95% CI 0.13 to 1.67, Analysis
4.2), though this is unlikely to be clinically signiﬁcant. The same
study found showed no clear differences between the compounds
in the short term using BPRS or Positive and Negative Syndrome
Scale (PANSS) overall. For other less important scores there was
some favouring of olanzapine over ﬂuphenazine and vice versa.
The clinical signiﬁcance of these ﬁndings is questionable due to
small sample sizes and wide conﬁdence intervals.
4.2 Adverse effects
Short- and mid-term data appeared to indicate less incidences of
any adverse effects with olanzapine. Data support the expected
outcome EPSEs with ﬂuphenazine and marked short-term weight
gain with olanzapine, but again, as with the other comparisons,
there was the risk of reporting bias favouring the newer drug.
4.3 Leaving the study early
No difference was found between the compounds for attrition
rates.
Overall completeness and applicability of
evidence
1. Applicability
There were no international multicentre trials. The majority of
patients were in-patients - thus these ﬁndings may not be applica-
ble to the larger number of patients with schizophrenia now living
in the community. Understandably, many of the exclusion criteria
related tomore severely ill patients (e.g. ’suicidality’ or “acute para-
noid psychosis”) again bringing into question the applicability of
these results in the acute in-patient setting. Similarly many other
physical and mental co-morbidities such as addiction or depres-
sion were exclusion criteria - in reality such co-morbidities tend
to be the norm rather than the exception.
Schizophrenia is a chronic, relapsing-remitting condition.None of
the trials lasted longer than22weeks (and three of the four less than
12 weeks). Thus these trials cannot provide data on ﬂuphenazine’s
role as a maintenance treatment in schizophrenia. Nor can they
provide essential safety information about the long-term health
implications of the studies drugs.
1.2 Quality of reporting
The four included studies failed to report several of our pre-spec-
iﬁed secondary outcomes of interest, including economic out-
comes, quality of life outcomes, service-use and hospitalisation
outcomes, relapse, and general function (such as social skills, em-
ployability). These are particularly patient-important outcomes
that have been overlooked, and would add to the body of evidence
regarding acceptability of treatment.
Each study had some examples of missing or unreported data due
to attrition. Attrition is inevitable but unfortunately these studies
had small-sample sizes.Only one gave details as towhy the patients
left the trial. Use of last observation carried forward (LOCF) was
not clearly stated.
Other common tendencies affect clinically meaningful interpre-
tation of the data - mean values were commonly reported with-
out standard deviations. Most of the global state and mental state
measurements were reported as continuous data that is difﬁcult to
interpret clinically. Amore meaningful measure might be achieved
by conversion to binary data such as “improved” or “not im-
proved.”
1.3 Heterogeneity
There was no heterogeneity between studies.
1.4 Publication bias
Formal tests to examine publication bias were underpowered.
Therefore, we can not make a judgement in this regard.
Quality of the evidence
The quality of the ﬁndings were all rated as “very low.” There were
concerns with all four trials about a lack of detailed descriptions
of the methodologies such as blinding and allocation practices.
Most of the studies were pharmaceutical industry-funded. Not
all outcomes were reported (particularly those related to adverse
events such as akathisia scales), which was suggestive of reporting
bias.
Potential biases in the review process
The review authors sought to adhere to the protocol, through the
independent inspection of citations and full articles of potentially
relevant studies.
Agreements and disagreements with other
studies or reviews
We are not aware of other systematic reviews evaluating the effects
of oral ﬂuphenazine versus atypical antipsychotics in the treatment
of schizophrenia.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
These studies do not provide clear information about the relative
merits or disadvantages of ﬂuphenazine compared to the atypical
antipsychotics many patients will be offered as ﬁrst-line treatment.
The data support the general point that use of ﬂuphenazine car-
ries the risk of many adverse effects including movement disorder.
Many outcomes that patients will be concerned with such as tol-
erability and effect on quality of life of the drug are not answered
by these studies.
2. For clinicians
These studies do not provide clear evidence to support or refute
use of ﬂuphenazine as ﬁrst-line treatment for schizophrenia com-
pared with atypical antipsychotics in terms of clinical response and
effectiveness. As expected, the evidence suggests a greater propen-
sity for EPSEs with ﬂuphenazine than amisulpride or olanzapine,
but more short-term weight gain with olanzapine and risperidone.
3. For managers or policy makers
Fluphenazine is inexpensive compared to atypical antipsychotics
but there are no cost-effectiveness data. Likewise, there are no clear
data relating to the relative effectiveness or patient satisfactionwith
the drug. It can cause signiﬁcant side effects such as movement
disorders.
Implications for research
1. General
Attempting to systematically review data on ﬂuphenazine high-
lights the necessity of studies conforming to certain minimum
criteria to allow extraction of clinically meaningful results. This
would include more detailed and transparent study protocols giv-
ing full disclosure to such things as allocation, randomisation and
blinding techniques. Use of more easily understandable binary
outcomes could be helpful, It should also be the case that all data
and results are fully reported. Two trials - Ravanic 1996 (excluded
study) and Djukic-Dejanovic 2002 (awaiting assessment) are of
direct relevance to this review but have no data that can be used.
We are not sure if the latter study should still be in awaiting as-
sessment, or merged with Ravanic 1996 as we continue to have
no record of the full publication. Furthermore, excluded studies
Boyer 1986 and Boyer 1996 may be one study. Close compliance
with CONSORT would have helped clarify these issues.
2. Specific
2.1 Reviews
The excluded studies and the one awaiting assessment do pose
important questions which would generate good comparisons for
other reviews (Table 3).
2.2 Trials
It is difﬁcult to derive meaningful clinical data to inform best
practice with regard to the use of ﬂuphenazine versus atypical
antipsychotics in schizophrenia despite access to the pooled data of
four different trials. Small sample sizes are problematic - it would
be beneﬁcial if international researchers were able to collaborate
in more multicentre and long-term studies. Studies should also
take into account more meaningful outcomes relating to hospital
admissions, quality of life, mortality and cost-effectiveness. Given
the current limitations in the literature, we propose a design for a
new randomised trial (Table 4).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Boyer 1987
Methods Allocation: randomised.
Blindness: not stated.
Duration: 3 weeks washout plus 6 weeks treatment period.
Setting: not stated.
Design: parallel.
Participants Diagnosis: schizophrenia (DSM-III).
N = 62.
Age: 21-53 years old.
Sex: 43 men, 19 women.
Duration ill: mean~12.3 years, SD~4.7 years.
Inclusion criteria: duration ill between 1 to 20 years; absence of marked positive symp-
toms; score >7 on DSAS
Exclusion criteria: not received antipsychotics in previous month
Interventions 1. Fluphenazine: 2 mg to 12 mg/day. N = 28.
2. Amisulpride: 50 mg to 300 mg/day. N = 34.
Outcomes Mental state: BPRS.*
Leaving the study early.
Unable to use -
Mental state: DSAS (not a validated scale).
Behaviour: NOSIE (no SD reported).
Adverse effects: physiological measures, CHESS (no data reported)
Notes * The published papers clearly report SD as measure of variance but these seem to be SE
and we treat them as such
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “After a 3-week washout period,
participants were randomly assigned” - no
further details. (p.296)
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Double-blind.
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Boyer 1987 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
High risk Five participants did not complete ratings
for various BPRS components
Selective reporting (reporting bias) High risk Did not report complete data for NOSIE
and CHESS.
Other bias Unclear risk None obvious.
Conley 2005
Methods Allocation: randomised, randomisation was performed by the dispensing pharmacy
Blindness: double-blind.
Duration: 12 weeks (with 4- to 6-week open-label qualiﬁcation phase prior to randomi-
sation)
Setting: in-patients, Maryland (USA)
Design: parallel.
Participants Diagnosis: schizophrenia (DSM-III); therapy-refractory.
N = 40.
Age:18-65 years old.
Sex: men = 30 and women = 8.
Length of illness: not stated.
Included criteria: persistent positive psychotic symptoms at study entry (“moderate”
severity≥ 4 points on a 1- to 7-point scale) on 2 of 4 psychosis items on the BPRS scale;
persistent global illness severity (BPRS total score ≥ 45 points on the 18-item scale and
a CGI score of ≥ 4 points [moderately ill]); two prior failed treatment trials with two
different antipsychotics at doses of 600 mg/day chlorpromazine equivalents, each of at
least 6 weeks duration; no stable period of good social/occupational functioning within
the previous 5 years
Exclusion criteria: not stated.
Interventions 1. Fluphenazine: mean, 13.2 mg/day, SD 1.17 mg/day, n = 13.
2. Risperidone: mean, 4.31 mg/day, SD 0.63 mg/day, n = 13.
3. Quetiapine: mean, 463.6 mg/day, SD 50.5 mg/day, n = 12.
Outcomes Clinically important response: no clinical improvement*.
Global state: CGI severity score.
Mental state: BPRS (global score; negative, positive, anxiety-depression score, hostility,
activation score)
Adverse effects.
Leave the study early.
Unable to use -
Simpson Angus Scale (SAS), the Barnes Akathisia Scale (BAS), and the Assessment of
Involuntary Movements Scale (AIMS), Sexual Function: Changes in Sexual Function
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Conley 2005 (Continued)
Questionnaire (CSFQ) (no data reported)
Quality of life (no SD reported).
Adverse effect: the Prolactin-Related Adverse Event Questionnaire (PRAEQ) (no data
reported)
Notes Funding: National Institutes of Mental Health (NIMH grant MH-47311); study med-
ications supplied by Janssen Pharmaceutica and Astra-Zeneca Pharmaceuticals
* decreased rate of BPRS score < 20%.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote:“randomisation was performed by
the dispensing pharmacy”.(p.341)
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “After a 4-6 week open-label trial
with either olanzapine (or a typical antipsy-
chotic other than ﬂuphenazine), partici-
pants who did not achieve a 20% reduction
in their total BPRS scores and who still had
a total BPRS≥35 points were randomly as-
signed. After open-label phase, participants
were randomised to double blind study.”
No further details.(p.164)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
High risk N = 40 participants randomised - n = 2
pieces of data “lost” (p.165); only results
for 38 participants reported
Selective reporting (reporting bias) High risk SAS, BAS, AIMS, NOSIE, CHESS,
CSFQ, PRAEQ were not well-reported
Other bias Unclear risk Funding: National Institutes of Mental
Health (NIMH grant MH-47311), study
medications supplied by Janssen Pharma-
ceutica and Astra-Zeneca Pharmaceuticals
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Dossenbach 1998
Methods Allocation: randomised, no further information.
Blindness: double-blind.
Duration: Acute phase: 6 weeks (2 to 9 days placebo lead-in); long term: 22 weeks
Setting: hospital, multicentre, Croatia.
Design: parallel.
Participants Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV)
N = 60.
Age: mean~35.4 years, SD~10.4 years.
Sex: men = 28 and women = 32.
Length of illness: not stated.
Inclusion criteria: schizophrenia, BPRS ≥ 42, CGI ≥ 4 .
Exclusion criteria: pregnant or lactating women, serious or unstable illness; history of
intolerance to olanzapine; DSM substance dependence excluding caffeine or nicotine
within last 30 days; serious suicide risk; signiﬁcantly elevated liver function results;
active hepatitis B or current jaundice; received treatment with injectable neuroleptic
within less than one dosing interval between depot neuroleptic injection prior to study
entry; previously intolerant or non-responsive to ﬂuphenazine; previous participation
in any olanzapine clinical trial; pregnancy or lactating; uncorrected hypothyroidism or
hyperthyroidism, myasthenia gravis, narrow-angle glaucoma, chronic urinary retention
and/or clinically signiﬁcant prostatic hypertrophy, a history of seizures, severe allergies
or multiple adverse drug reactions, a history of leukopenia without known aetiology
Interventions 1. Fluphenazine: 5 mg to 20 mg/day, average, 11.7 ± 3.0 mg/day for acute phase (6
weeks) and 11.7 ± 3.0 mg/day for long term (22 weeks), n = 30
2. Olanzapine: 6 mg to 21 mg/day, average, 13.6 ± 2.4 mg/day for acute phase (6 weeks)
and 14.8 ± 2.5 mg/day for long term (22 weeks), n = 30
Outcomes Clinically important response: no clinical improvement*.
Global state: CGI severity change score.
Mental state: BPRS (global score; negative, positive change score); PANSS (total, positive,
negative, general psychopathology change score), Hillside Akathisia Scale (HAS)
Quality of Sleep scale: Leeds Sleep Evaluation Questionnaire (LSEQ) total and subscale
score
Satisfaction: Drug Attitude Inventory (DAI).
Extrapyramidal adverse effects: Simpson Angus Scale (SAS), and the Assessment of In-
voluntary Movements Scale (AIMS)
Leave the study early.
Unable to use: vital signs, ECG, laboratory ﬁndings, no data reported. HAMA subscale
score. LSEQ in medium term, data not reported
Notes Funding: Eli Lilly and Company.
*Two deﬁnitions: decreased rate of PANSS score < 40%, decreased rate of BPRS score <
40%.The datawere reported separately in our data analysis based on these two deﬁnitions
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Dossenbach 1998 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quotes: “Random allocation at a 1:1 ratio”
(p.312)
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Thiswas a long-term, randomised,
double-blind parallel clinical trial” (p.312)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote:“This was a long-term, randomised,
double-blind parallel clinical trial” (p.312)
Incomplete outcome data (attrition bias)
All outcomes
High risk Out of 60 participants, ﬁve (n = 3 olan-
zapine; n = 2 ﬂuphenazine) were excluded
from efﬁcacy analysis because they did not
meet inclusion criteria for BPRS or CGI.
Three participants missing from DAI re-
sults because of no baseline data for two (n
= 1 olanzapine; n = 1 ﬂuphenazine) and one
participant on ﬂuphenazine discontinuing
without having aDAIperformed. Four par-
ticipants in ﬂuphenazine group discontin-
ued because of adverse event. All partici-
pants were included in safety analysis
Selective reporting (reporting bias) Low risk All measured outcomes were well reported.
Other bias High risk Funding: sponsored by Eli Lilly and Com-
pany.
Saletu 1994
Methods Allocation: randomised,no further details.
Blindness: double-blind.
Duration: 3-day washout period plus 6 weeks treatment period
Setting: in-patients, Austria.
Design: parallel.
Participants Diagnosis: DSM-III schizophrenia.
N = 40.
Age: mean~31 years,SD~6.4 years.
Sex: men = 32 and women = 8.
Length of illness: mean 82.6~118.3 months.
Inclusion criteria:clinical diagnosis (ICD 9 criteria) of either a simple type (295.0),
hebephrenic type (295.1) or residual type (295.6) of schizophrenia; minimal age of 18
years; minimal length of illness of 1 year; a necessity of 6 weeks in-patient treatment
Exclusion criteria: an acute phase of a paranoid schizophrenia; pronounced symptoms of
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Saletu 1994 (Continued)
depression, neurotic asthenia or neurotic depression; reactive depressive psychosis; alco-
hol-induced psychiatric disturbances; gravidity; physical illness; treatment with lithium
salts; treatment with depot neuroleptics within the last 45 days; potential premature
discontinuation of treatment
Interventions 1. Fluphenazine: 2 mg/day to 4 mg/day, n = 21.
2. Amisulpride: 50 mg/day to 100 mg/day, n = 19.
During the ﬁrst 2 weeks, the dosage consisted of single doses of 50 mg/day amisulpride
or 2 mg/day ﬂuphenazine. From the third week up to the sixth, the daily doses were 100
mg amisulpride (50 mg twice daily) and 4 mg ﬂuphenazine (2 mg twice daily)
Outcomes Global state: CGI
Mental state: Association for Methodology and Documentation in Psychiatry (AMDP)
, SANS
Extrapyramidal adverse effects: Webster scale, contaminant of anticholinergic drugs
Adverse effect: Adverse experience questionnaire.
Leave the study early.
Unable to use:
Global function: Grunberger AD test (Alphabetical cross-out test); Grunberger psy-
chomotor activity test; numerical memory test; Pauli test; reaction time test; complex
reaction test; Zerssen well-being scale; semantic differential polarity proﬁle; state-trait
anxiety scale; CFF descending threshold; skin conductance (mean); skin conductance
ﬂuctuations. There is no SD reported and no reply from the author
Webster scale, Adverse experience questionnaire, EEG, no data reported on this outcome
Notes Funding: Experimental drugs supplied by Synthelabo Recherche/Laboratoires Dela-
grange (Bagneux, France)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “patients were included in the dou-
ble-blind, parallel group study” (p.127)
Allocation concealment (selection bias) Unclear risk Allocation concealment not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote:“patients were included in the dou-
ble-blind, parallel group study” (p.127)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “patients were included in the dou-
ble-blind, parallel group study” (p.127)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Out of 40 participants, ﬁve discontinued
therapy prematurely. Three amisulpride
participants dropped out due to productive
symptoms (days 14, 28 and 35) while two
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Saletu 1994 (Continued)
ﬂuphenazine participants dropped out due
to depressive symptoms (days 21 and 28)
Selective reporting (reporting bias) High risk Webster scale, adverse experience question-
naire and EEG were not reported
Other bias High risk Funding: Experimental drugs supplied by
Synthelabo Recherche/Laboratoires Dela-
grange (Bagneux, France)
AIMS - Assessment of Involuntary Movements Scale
AMDP - Association for Methodology and Documentation in Psychiatry
BAS - Barnes Akathisa Scale
BPRS - Brief Psychiatric Rating Scale
CFF: critical ﬂicker frequency
CGI - Cognitive Global Impression
CHESS - Changes in Health, End-Stage, Disease, Signs, and Symptoms
CSFQ - Changes in Sexual Functioning Questionnaire
DAI - Drug Attitude Inventory
DSAS - Depression Anxiety and Stress Scale
DSM-III: Diagnostic and Statistical Manual, third edition
DSM-IV: Diagnostic and Statistical Manual, fourth edition
ECG - electrocardiogram
HAMA - Hamilton Anxiety Scale
HAS - Hillside Akathisia Scale
ICD: International Classiﬁcation of Diseases
LSEQ - Leeds Sleep Evaluation Questionnaire
NOSIE - Nurses’ Observation Scale for Inpatient Evaluation
PANSS - Positive and Negative Syndrome Scale
PRAEQ - Prolactin Related Adverse Event Questionnaire
SANS - Scale for Assessment of Negative Symptoms
SAS - Simpson-Angus Scale
SD: standard deviation
SE: standard error
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Boyer 1986 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: amisulpride versus haloperidol (n = 39), not ﬂuphenazine
We are unclear if this study is one report of a larger multicentre trial (Boyer 1996).
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(Continued)
Boyer 1987a Allocation: randomised.
Participants: people with schizophrenia.
Interventions: amisulpride 100 mg versus amisulpride 300 mg versus placebo, not ﬂuphenazine
Boyer 1996 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: amisulpride versus haloperidol (n = 191), not ﬂuphenazine
We are unclear if this study is the ﬁnal report of trial also reported by individual centre (Boyer 1986).
Pickar 1992 Allocation: not randomised, one arm cross-over design.
Ravanic 1996 Allocation: randomised.
Paticipants: schizophrenia DSM III-R.
Intervention: ﬂuphenazine versus clozapine.
Outcomes: no usable data.
DSM-III-R: Diagnostic and Statistical Manual, third edition, revised
Characteristics of studies awaiting assessment [ordered by study ID]
Djukic-Dejanovic 2002
Methods Allocation: randomised.
Participants Diagnosis: schizophrenia (DSM-IV).
N = 44.
Interventions 1. Fluphenazine. N = 10.
2. Clozapine. N = 23.
3. Haloperidol. N = 11.
Outcomes Adverse effects.
Notes Full paper required (conference abstract only)
We are very unclear if this study is one further report of the Ravanic 1996 trial. Numbers of participants, and the
short description is identical but interventions are similar but not the same
DSM-IV: Diagnostic and Statistical Manual, fourth edition
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D A T A A N D A N A L Y S E S
Comparison 1. FLUPHENAZINE (ORAL) vs AMISULPRIDE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global state: 1. Average endpoint
score of CGI scales (high =
poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 short term (up to 12
weeks)
1 36 Mean Difference (IV, Random, 95% CI) -0.34 [-0.90, 0.22]
2 Mental state: 2a. Average
endpoint score of various scales
(high = poor)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 BPRS - anxiety/depression
subscale score - short term (up
to 12 weeks)
1 57 Mean Difference (IV, Random, 95% CI) 2.60 [1.40, 3.80]
2.2 BPRS total score - short
term (up to 12 weeks)
1 57 Mean Difference (IV, Random, 95% CI) 5.10 [-2.35, 12.55]
2.3 SANS total score - short
term (up to 12 weeks)
1 36 Mean Difference (IV, Random, 95% CI) -9.49 [-17.88, -1.10]
3 Mental state: 2b. Average
endpoint score of AMDP scale
(high = poor)
Other data No numeric data
3.1 short term (up to 12
weeks)
Other data No numeric data
4 Adverse effects: 1.
Extrapyramidal effects
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 concomitant
anticholinergic medication -
short term (up to 12 weeks)
1 36 Risk Ratio (M-H, Random, 95% CI) 7.82 [1.07, 57.26]
5 Leaving the study early 2 Risk Ratio (IV, Random, 95% CI) Subtotals only
5.1 any reason 2 98 Risk Ratio (IV, Random, 95% CI) 1.19 [0.63, 2.28]
5.2 adverse effects - short term
(up to 12 weeks)
2 98 Risk Ratio (IV, Random, 95% CI) 1.88 [0.24, 14.68]
5.3 inefﬁcacy - short term (up
to 12 weeks)
2 98 Risk Ratio (IV, Random, 95% CI) 1.82 [0.68, 4.84]
5.4 productive symptoms -
short term (up to 12 weeks)
1 36 Risk Ratio (IV, Random, 95% CI) 0.37 [0.04, 3.25]
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Comparison 2. FLUPHENAZINE (ORAL) vs RISPERIDONE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinically important response
(deﬁned by study)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 short term (up to 12
weeks)
1 26 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.13, 3.35]
2 Global state: 1. Average endpoint
score of CGI scales (high =
poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 short term (up to 12
weeks)
1 26 Mean Difference (IV, Random, 95% CI) 0.07 [-0.77, 0.91]
3 Mental state: 2a. Average
endpoint scores (BPRS, high =
poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 BPRS endpoint total scale
score - short term (up to 12
weeks)
1 25 Mean Difference (IV, Random, 95% CI) -1.98 [-12.96, 9.00]
3.2 BPRS positive subscale
score - short term (up to 12
weeks)
1 25 Mean Difference (IV, Random, 95% CI) -0.15 [-4.22, 3.92]
3.3 BPRS negative subscale
score - short term (up to 12
weeks)
1 25 Mean Difference (IV, Random, 95% CI) -1.54 [-3.94, 0.86]
3.4 BPRS hostile subscale
score - short term (up to 12
weeks)
1 25 Mean Difference (IV, Random, 95% CI) 0.92 [-2.21, 4.05]
4 Mental state: 2b. Average
endpoint score of various scales
(high = poor) - short term (up
to 12 weeks) (skewed data)
Other data No numeric data
4.1 BPRS anxiety/depression
subscale score
Other data No numeric data
4.2 BPRS activation subscale
score
Other data No numeric data
5 Adverse effects: 1.
Anticholinergic effect
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 blurred vision - short term
(up to 12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.18, 6.53]
5.2 dry mouth - short term
(up to 12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.18, 6.53]
5.3 urinary hesitancy - short
term (up to 12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 5.38 [0.28, 101.96]
6 Adverse effects: 2. Central
nervous system
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 anxiety - short term (up to
12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.06, 5.24]
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6.2 headache - short term (up
to 12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.33, 1.79]
6.3 lethargy - short term (up
to 12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.23, 2.91]
6.4 insomnia - short term (up
to 12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 1.81 [0.55, 5.98]
6.5 somnolence - short term
(up to 12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.30, 2.49]
7 Adverse effects: 3.
Gastrointestinal
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 constipation - short term
(up to 12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 9.69 [0.58, 163.02]
7.2 diarrhoea - short term (up
to 12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.01, 4.08]
7.3 dyspepsia - short term (up
to 12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 3.25 [0.39, 27.15]
7.4 nausea/vomiting - short
term (up to 12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.14, 3.61]
8 Adverse effects: 4. Other adverse
events
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 urinary frequency - short
term (up to 12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.02, 8.05]
8.2 orthostasis - short term
(up to 12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.10, 1.83]
8.3 increased appetite - short
term (up to 12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.14, 3.61]
8.4 dizziness - short term (up
to 12 weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.04, 3.02]
9 Adverse effects: 5. Average
endpoint weight loss (kg)
(skewed data)
Other data No numeric data
9.1 short term (up to 12
weeks)
Other data No numeric data
10 Leaving the study early 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
10.1 inefﬁcacy - short term
(up to 12 weeks)
1 25 Risk Ratio (IV, Random, 95% CI) 1.08 [0.08, 15.46]
Comparison 3. FLUPHENAZINE (ORAL) vs QUETIAPINE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinically important response
(deﬁned by study)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 short term (up to 12
weeks)
1 25 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.12, 3.07]
2 Global state: 1. CGI: Average
endpoint CGI-SI (high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
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2.1 short term (up to 12
weeks)
1 25 Mean Difference (IV, Random, 95% CI) -0.03 [-0.92, 0.86]
3 Mental state: 2a. General -
average endpoint score (BPRS
total, high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 short term (up to 12
weeks)
1 25 Mean Difference (IV, Random, 95% CI) -1.98 [-12.96, 9.00]
4 Mental state: 2b. Positive
symptoms - average endpoint
score (BPRS positive sub-score,
high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 short term (up to 12
weeks)
1 25 Mean Difference (IV, Random, 95% CI) -13.61 [-20.77, -6.
45]
5 Mental state: 2c. Negative
symptoms - average endpoint
score (BPRS negative sub-score,
high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 short term (up to 12
weeks)
1 24 Mean Difference (IV, Random, 95% CI) -0.11 [-2.27, 2.05]
6 Mental state: 2d.
Anxiety/depression symptoms -
average endpoint score (BPRS
anxiety/depression sub-score,
high score = poor)
Other data No numeric data
6.1 short term (up to 12
weeks)
Other data No numeric data
7 Mental state: 2e. Hostility
symptoms - average endpoint
score (BPRS hostility sub-score,
high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 short term (up to 12
weeks)
1 24 Mean Difference (IV, Random, 95% CI) 0.79 [-2.45, 4.03]
8 Mental state: 2f. Activation
symptoms - average endpoint
score (BPRS activation
sub-score, high = poor)
Other data No numeric data
8.1 short term (up to 12
weeks)
Other data No numeric data
9 Adverse effects: 1.
Anticholinergic effect
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 dry mouth - short term
(up to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.17, 5.98]
9.2 blurred vision - short term
(up to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.17, 5.98]
9.3 urinary hesitancy - short
term (up to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.17, 5.98]
10 Adverse effects: 2. Central
nervous system
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 anxiety - short term (up
to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.07, 14.21]
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10.2 headache - short term
(up to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.39, 2.58]
10.3 insomnia - short term
(up to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 1.67 [0.51, 5.46]
10.4 lethargy - short term (up
to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 1.5 [0.30, 7.43]
10.5 somnolence - short term
(up to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.38, 4.72]
11 Adverse effects: 3.
Gastrointerstinal adverse effects
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 constipation - short term
(up to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.32, 3.10]
11.2 diarrhoea - short term
(up to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 0.2 [0.01, 3.77]
11.3 dyspepsia - short term
(up to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.36, 24.92]
11.4 nausea/ vomiting - short
term (up to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.21, 19.23]
12 Adverse effects: 4a. Other
adverse events
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 dizziness - short term (up
to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.07, 14.21]
12.2 increased appetite - short
term (up to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.13, 3.30]
12.3 orthostasis - short term
(up to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.21, 19.23]
12.4 urinary frequency - short
term (up to 12 weeks)
1 24 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.01, 7.45]
13 Adverse effects: 4b. Other -
average endpoint weight loss
(average weight in kg) (skewed)
Other data No numeric data
13.2 short term (up to 12
weeks)
Other data No numeric data
14 Leaving the study early 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
14.1 inefﬁcacy - short term
(up to 12 weeks)
1 25 Risk Ratio (IV, Random, 95% CI) 0.46 [0.05, 4.46]
14.2 adverse effects - short
term (up to 12 weeks)
1 25 Risk Ratio (IV, Random, 95% CI) 0.19 [0.01, 3.52]
Comparison 4. FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinically important response
(deﬁned by author)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 short term (up to 12
weeks)
1 60 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.86, 2.07]
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1.2 medium term (13 to 26
weeks)
1 60 Risk Ratio (M-H, Random, 95% CI) 1.6 [0.87, 2.94]
2 Global state: 1. CGI: Average
change CGI-SI (high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 short term (up to 12
weeks)
1 55 Mean Difference (IV, Random, 95% CI) 0.7 [-0.01, 1.41]
2.2 medium term (13 to 26
weeks)
1 55 Mean Difference (IV, Random, 95% CI) 0.90 [0.13, 1.67]
3 Mental state: 2a. General -
average change score (BPRS
total, high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 short term (up to 12
weeks)
1 54 Mean Difference (IV, Random, 95% CI) 7.1 [-1.15, 15.35]
3.2 medium term (13 to 26
weeks)
1 54 Mean Difference (IV, Random, 95% CI) 9.3 [0.10, 18.50]
4 Mental state: 2b. General -
average change score (PANSS
total, high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 short term (up to 12
weeks)
1 54 Mean Difference (IV, Random, 95% CI) 12.0 [-2.03, 26.03]
4.2 medium term (13 to 26
weeks)
1 54 Mean Difference (IV, Random, 95% CI) 16.20 [0.41, 31.99]
5 Mental state: 2c. Positive
symptoms - average change
score (BPRS positive sub-score,
high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 short term (up to 12
weeks)
1 55 Mean Difference (IV, Random, 95% CI) 2.3 [-0.67, 5.27]
5.2 medium term (13 to 26
weeks)
1 55 Mean Difference (IV, Random, 95% CI) 2.90 [-0.29, 6.09]
6 Mental state: 2d. Positive
symptoms - average endpoint
score (PANSS positive
sub-score, high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 short term (up to 12
weeks)
1 55 Mean Difference (IV, Random, 95% CI) -5.1 [-9.68, -0.52]
6.2 medium term (13 to 26
weeks)
1 55 Mean Difference (IV, Random, 95% CI) -5.1 [-9.82, -0.38]
7 Mental state: 2e. Negative
symptoms - average change
score (BPRS negative sub-score,
high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 short term (up to 12
weeks)
1 55 Mean Difference (IV, Random, 95% CI) 1.20 [-0.47, 2.87]
7.2 medium term (13 to 26
weeks)
1 55 Mean Difference (IV, Random, 95% CI) 1.70 [-0.31, 3.71]
8 Mental state: 2f. Negative
symptoms - average change
score (PANSS negative
sub-score, high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
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8.1 short term (up to 12
weeks)
1 54 Mean Difference (IV, Random, 95% CI) 2.40 [-0.96, 5.76]
8.2 medium term (13 to 26
weeks)
1 54 Mean Difference (IV, Random, 95% CI) 3.0 [-1.22, 7.22]
9 Mental state: 2g. General
psychopathology - average
change score (PANSS general
psychopathology sub-score,
high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 short term (up to 12
weeks)
1 54 Mean Difference (IV, Random, 95% CI) 6.20 [-0.90, 13.30]
9.2 medium term (13 to 26
weeks)
1 54 Mean Difference (IV, Random, 95% CI) 8.2 [0.43, 15.97]
10 Mental state: 2h. Anxiety -
average change score (HAMA,
high = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 short term (up to 12
weeks)
1 54 Mean Difference (IV, Random, 95% CI) 4.00 [0.08, 7.92]
10.2 medium term (13 to 26
weeks)
1 59 Mean Difference (IV, Random, 95% CI) 6.0 [-0.12, 12.12]
11 Satisfaction with treatment: 1.
Average change score (DAI,
low = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 short term (up to 12
weeks)
1 52 Mean Difference (IV, Random, 95% CI) -1.2 [-2.44, 0.04]
11.2 medium term (13 to 26
weeks)
1 52 Mean Difference (IV, Random, 95% CI) -1.1 [-2.08, -0.12]
12 Adverse effects: 1. General 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
12.1 at least one adverse effect
- medium term (13 to 26
weeks)
1 60 Risk Ratio (IV, Random, 95% CI) 1.53 [1.02, 2.31]
13 Adverse effects: 2.
Anticholinergic effect
1 Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 concomitant
anticholinergic medication
- average endpoint dosage
(mg/d) - short term (up to 12
weeks)
1 60 Mean Difference (IV, Random, 95% CI) 0.89 [0.35, 1.43]
13.2 concomitant
anticholinergic medication
- average endpoint dosage
(mg/d) - medium term (13 to
26 weeks)
1 60 Mean Difference (IV, Random, 95% CI) 1.08 [0.28, 1.88]
14 Adverse effects: 3a. Central
nervous system
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 insomnia - short term
(up to 12 weeks)
1 60 Risk Ratio (M-H, Random, 95% CI) 13.0 [0.76, 220.96]
15 Adverse effects: 3b. CNS
(LSEQ, low = poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
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15.1 awakening from sleep
average endpoint score - short
term (up to 12 weeks)
1 53 Mean Difference (IV, Random, 95% CI) -2.7 [-10.18, 4.78]
15.2 behaviour following
wakefulness average endpoint
score - short term (up to 12
weeks)
1 53 Mean Difference (IV, Random, 95% CI) -6.60 [-13.92, 0.72]
15.3 getting to sleep average
endpoint score - short term (up
to 12 weeks)
1 53 Mean Difference (IV, Random, 95% CI) -4.4 [-14.18, 5.38]
15.4 sleep quality - average
endpoint score - short term (up
to 12 weeks)
1 53 Mean Difference (IV, Random, 95% CI) -6.10 [-15.97, 3.77]
16 Adverse effects: 4a.
Extrapyramidal effects
1 Risk Ratio (IV, Random, 95% CI) Subtotals only
16.1 akathisia - short term (up
to 12 weeks)
1 60 Risk Ratio (IV, Random, 95% CI) 3.0 [0.90, 10.01]
16.2 hypertonia - short term
(up to 12 weeks)
1 60 Risk Ratio (IV, Random, 95% CI) 3.0 [0.33, 27.23]
16.3 tremor - short term (up
to 12 weeks)
1 60 Risk Ratio (IV, Random, 95% CI) 1.0 [0.22, 4.56]
17 Adverse effects: 4b.
Extrapyramidal effects - average
change score (SAS, high =
poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
17.1 short term (up to 12
weeks)
1 60 Mean Difference (IV, Random, 95% CI) 4.20 [1.68, 6.72]
17.2 medium term (13 to 26
weeks)
1 60 Mean Difference (IV, Random, 95% CI) 4.0 [1.02, 6.98]
18 Adverse effects: 4c.
Extrapyramidal effects - average
change score (HAS, high =
poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
18.1 short term (up to 12
weeks)
1 59 Mean Difference (IV, Random, 95% CI) 6.6 [0.88, 12.32]
18.2 medium term (13 to 26
weeks)
1 59 Mean Difference (IV, Random, 95% CI) 6.0 [-0.12, 12.12]
19 Adverse effects: 4d.
Extrapyramidal effects - average
change score (AIMS, high =
poor)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 short term (up to 12
weeks)
1 60 Mean Difference (IV, Random, 95% CI) 1.1 [-0.11, 2.31]
19.2 medium term (13 to 26
weeks)
1 60 Mean Difference (IV, Random, 95% CI) 1.1 [-0.45, 2.65]
20 Adverse effects: 5. Other
adverse events
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
20.1 weight gain - medium
term (13 to 26 weeks)
1 60 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.01, 1.57]
21 Adverse effects: 5b. Other
adverse events
1 Mean Difference (IV, Random, 95% CI) Subtotals only
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21.1 concomitant anxiolytics
medication average dosage
(mg/d) - short term (up to 12
weeks)
1 60 Mean Difference (IV, Random, 95% CI) 4.65 [0.07, 9.23]
21.2 concomitant anxiolytics
medication - average dosage
(mg/d)- medium term (13 to
26 weeks)
1 60 Mean Difference (IV, Random, 95% CI) 6.10 [0.63, 11.57]
21.3 effects on physiology -
supine systolic blood pressure
(average in mmHg) - short
term (up to 12 weeks)
1 60 Mean Difference (IV, Random, 95% CI) -10.0 [-18.11, -1.89]
21.4 effects on physiology -
supine systolic blood pressure
(average in mmHg) - medium
term (13 to 26 weeks)
1 60 Mean Difference (IV, Random, 95% CI) -10.0 [-18.11, -1.89]
22 Adverse effects: 5c. Other
(skewed)
Other data No numeric data
22.1 weight gain (average
weight in kg) - short term (up
to 12 weeks)
Other data No numeric data
22.2 weight gain (average
weight in kg) - medium term
(13 to 26 weeks)
Other data No numeric data
23 Leaving the study early 1 Risk Ratio (IV, Random, 95% CI) Subtotals only
23.1 inefﬁcacy - short term
(up to 12 weeks)
1 60 Risk Ratio (IV, Random, 95% CI) 3.0 [0.33, 27.23]
23.2 adverse effects - medium
term (13 to 26 weeks)
1 60 Risk Ratio (IV, Random, 95% CI) 9.00 [0.51, 160.17]
Analysis 1.1. Comparison 1 FLUPHENAZINE (ORAL) vs AMISULPRIDE, Outcome 1 Global state: 1.
Average endpoint score of CGI scales (high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 1 FLUPHENAZINE (ORAL) vs AMISULPRIDE
Outcome: 1 Global state: 1. Average endpoint score of CGI scales (high = poor)
Study or subgroup Fluphenazine (oral) Amisulpride
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Saletu 1994 17 5.13 (1.02) 19 5.47 (0.62) 100.0 % -0.34 [ -0.90, 0.22 ]
Subtotal (95% CI) 17 19 100.0 % -0.34 [ -0.90, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
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Analysis 1.2. Comparison 1 FLUPHENAZINE (ORAL) vs AMISULPRIDE, Outcome 2 Mental state: 2a.
Average endpoint score of various scales (high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 1 FLUPHENAZINE (ORAL) vs AMISULPRIDE
Outcome: 2 Mental state: 2a. Average endpoint score of various scales (high = poor)
Study or subgroup Fluphenazine (oral) Amisulpride
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BPRS - anxiety/depression subscale score - short term (up to 12 weeks)
Boyer 1987 25 8.7 (3) 32 6.1 (0.68) 100.0 % 2.60 [ 1.40, 3.80 ]
Subtotal (95% CI) 25 32 100.0 % 2.60 [ 1.40, 3.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.25 (P = 0.000021)
2 BPRS total score - short term (up to 12 weeks)
Boyer 1987 25 42.3 (11) 32 37.2 (17.54) 100.0 % 5.10 [ -2.35, 12.55 ]
Subtotal (95% CI) 25 32 100.0 % 5.10 [ -2.35, 12.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
3 SANS total score - short term (up to 12 weeks)
Saletu 1994 17 40.88 (13.82) 19 50.37 (11.59) 100.0 % -9.49 [ -17.88, -1.10 ]
Subtotal (95% CI) 17 19 100.0 % -9.49 [ -17.88, -1.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.027)
Test for subgroup differences: Chi2 = 8.33, df = 2 (P = 0.02), I2 =76%
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Analysis 1.3. Comparison 1 FLUPHENAZINE (ORAL) vs AMISULPRIDE, Outcome 3 Mental state: 2b.
Average endpoint score of AMDP scale (high = poor).
Mental state: 2b. Average endpoint score of AMDP scale (high = poor)
Study Interventions Mean SD N
short term (up to 12 weeks) short term (up t
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Mental state: 2b. Average endpoint score of AMDP scale (high = poor) (Continued)
Saletu 1994 Fluphenazine 7.13 4.26 17
Saletu 1994 Amisulpride 8.76 4.13 19
Analysis 1.4. Comparison 1 FLUPHENAZINE (ORAL) vs AMISULPRIDE, Outcome 4 Adverse effects: 1.
Extrapyramidal effects.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 1 FLUPHENAZINE (ORAL) vs AMISULPRIDE
Outcome: 4 Adverse effects: 1. Extrapyramidal effects
Study or subgroup Fluphenazine (oral) Amisulpride Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 concomitant anticholinergic medication - short term (up to 12 weeks)
Saletu 1994 7/17 1/19 100.0 % 7.82 [ 1.07, 57.26 ]
Subtotal (95% CI) 17 19 100.0 % 7.82 [ 1.07, 57.26 ]
Total events: 7 (Fluphenazine (oral)), 1 (Amisulpride)
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.043)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 FLUPHENAZINE (ORAL) vs AMISULPRIDE, Outcome 5 Leaving the study
early.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 1 FLUPHENAZINE (ORAL) vs AMISULPRIDE
Outcome: 5 Leaving the study early
Study or subgroup Fluphenazine (oral) Amisulpride Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 any reason
Boyer 1987 10/28 10/34 80.5 % 1.21 [ 0.59, 2.49 ]
Saletu 1994 3/17 3/19 19.5 % 1.12 [ 0.26, 4.81 ]
Subtotal (95% CI) 45 53 100.0 % 1.19 [ 0.63, 2.28 ]
Total events: 13 (Fluphenazine (oral)), 13 (Amisulpride)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
2 adverse effects - short term (up to 12 weeks)
Boyer 1987 1/28 1/34 57.0 % 1.21 [ 0.08, 18.55 ]
Saletu 1994 1/17 0/19 43.0 % 3.33 [ 0.14, 76.75 ]
Subtotal (95% CI) 45 53 100.0 % 1.88 [ 0.24, 14.68 ]
Total events: 2 (Fluphenazine (oral)), 1 (Amisulpride)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
3 inefficacy - short term (up to 12 weeks)
Boyer 1987 7/28 5/34 90.2 % 1.70 [ 0.61, 4.78 ]
Saletu 1994 1/17 0/19 9.8 % 3.33 [ 0.14, 76.75 ]
Subtotal (95% CI) 45 53 100.0 % 1.82 [ 0.68, 4.84 ]
Total events: 8 (Fluphenazine (oral)), 5 (Amisulpride)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
4 productive symptoms - short term (up to 12 weeks)
Saletu 1994 1/17 3/19 100.0 % 0.37 [ 0.04, 3.25 ]
Subtotal (95% CI) 17 19 100.0 % 0.37 [ 0.04, 3.25 ]
Total events: 1 (Fluphenazine (oral)), 3 (Amisulpride)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Chi2 = 1.91, df = 3 (P = 0.59), I2 =0.0%
0.01 0.1 1 10 100
Fluphenazine (oral) Amisulpride
65Fluphenazine (oral) versus atypical antipsychotics for schizophrenia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 FLUPHENAZINE (ORAL) vs RISPERIDONE, Outcome 1 Clinically important
response (defined by study).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 2 FLUPHENAZINE (ORAL) vs RISPERIDONE
Outcome: 1 Clinically important response (defined by study)
Study or subgroup Fluphenazine (oral) Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term (up to 12 weeks)
Conley 2005 2/13 3/13 100.0 % 0.67 [ 0.13, 3.35 ]
Subtotal (95% CI) 13 13 100.0 % 0.67 [ 0.13, 3.35 ]
Total events: 2 (Fluphenazine (oral)), 3 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 FLUPHENAZINE (ORAL) vs RISPERIDONE, Outcome 2 Global state: 1.
Average endpoint score of CGI scales (high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 2 FLUPHENAZINE (ORAL) vs RISPERIDONE
Outcome: 2 Global state: 1. Average endpoint score of CGI scales (high = poor)
Study or subgroup Fluphenazine (oral) Risperidone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Conley 2005 13 5.15 (1.28) 13 5.08 (0.86) 100.0 % 0.07 [ -0.77, 0.91 ]
Subtotal (95% CI) 13 13 100.0 % 0.07 [ -0.77, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 FLUPHENAZINE (ORAL) vs RISPERIDONE, Outcome 3 Mental state: 2a.
Average endpoint scores (BPRS, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 2 FLUPHENAZINE (ORAL) vs RISPERIDONE
Outcome: 3 Mental state: 2a. Average endpoint scores (BPRS, high = poor)
Study or subgroup Fluphenazine (oral) Risperidone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 BPRS endpoint total scale score - short term (up to 12 weeks)
Conley 2005 13 51.85 (14.87) 12 53.83 (13.14) 100.0 % -1.98 [ -12.96, 9.00 ]
Subtotal (95% CI) 13 12 100.0 % -1.98 [ -12.96, 9.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
2 BPRS positive subscale score - short term (up to 12 weeks)
Conley 2005 12 17.31 (5.96) 13 17.46 (4.18) 100.0 % -0.15 [ -4.22, 3.92 ]
Subtotal (95% CI) 12 13 100.0 % -0.15 [ -4.22, 3.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
3 BPRS negative subscale score - short term (up to 12 weeks)
Conley 2005 12 6.31 (2.43) 13 7.85 (3.63) 100.0 % -1.54 [ -3.94, 0.86 ]
Subtotal (95% CI) 12 13 100.0 % -1.54 [ -3.94, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
4 BPRS hostile subscale score - short term (up to 12 weeks)
Conley 2005 12 10.54 (4.68) 13 9.62 (3.07) 100.0 % 0.92 [ -2.21, 4.05 ]
Subtotal (95% CI) 12 13 100.0 % 0.92 [ -2.21, 4.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Chi2 = 1.60, df = 3 (P = 0.66), I2 =0.0%
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Analysis 2.4. Comparison 2 FLUPHENAZINE (ORAL) vs RISPERIDONE, Outcome 4 Mental state: 2b.
Average endpoint score of various scales (high = poor) - short term (up to 12 weeks) (skewed data).
Mental state: 2b. Average endpoint score of various scales (high = poor) - short term (up to 12 weeks) (skewed data)
Study Interventions Mean SD N
BPRS anxiety/depression subscale score BPRS anxiety/d
Conley 2005 Fluphenazine 10.38 5.20 12
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Mental state: 2b. Average endpoint score of various scales (high = poor) - short term (up to 12weeks) (skewed data) (Continued)
Conley 2005 Risperidone 9.31 5.91 13
BPRS activation subscale score BPRS activation
Conley 2005 Fluphenazine 7.00 3.72 12
Conley 2005 Risperidone 7.00 3.06 13
Analysis 2.5. Comparison 2 FLUPHENAZINE (ORAL) vs RISPERIDONE, Outcome 5 Adverse effects: 1.
Anticholinergic effect.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 2 FLUPHENAZINE (ORAL) vs RISPERIDONE
Outcome: 5 Adverse effects: 1. Anticholinergic effect
Study or subgroup Fluphenazine (oral) Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 blurred vision - short term (up to 12 weeks)
Conley 2005 2/12 2/13 100.0 % 1.08 [ 0.18, 6.53 ]
Subtotal (95% CI) 12 13 100.0 % 1.08 [ 0.18, 6.53 ]
Total events: 2 (Fluphenazine (oral)), 2 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
2 dry mouth - short term (up to 12 weeks)
Conley 2005 2/12 2/13 100.0 % 1.08 [ 0.18, 6.53 ]
Subtotal (95% CI) 12 13 100.0 % 1.08 [ 0.18, 6.53 ]
Total events: 2 (Fluphenazine (oral)), 2 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
3 urinary hesitancy - short term (up to 12 weeks)
Conley 2005 2/12 0/13 100.0 % 5.38 [ 0.28, 101.96 ]
Subtotal (95% CI) 12 13 100.0 % 5.38 [ 0.28, 101.96 ]
Total events: 2 (Fluphenazine (oral)), 0 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Chi2 = 0.96, df = 2 (P = 0.62), I2 =0.0%
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Analysis 2.6. Comparison 2 FLUPHENAZINE (ORAL) vs RISPERIDONE, Outcome 6 Adverse effects: 2.
Central nervous system.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 2 FLUPHENAZINE (ORAL) vs RISPERIDONE
Outcome: 6 Adverse effects: 2. Central nervous system
Study or subgroup Fluphenazine (oral) Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 anxiety - short term (up to 12 weeks)
Conley 2005 1/12 2/13 100.0 % 0.54 [ 0.06, 5.24 ]
Subtotal (95% CI) 12 13 100.0 % 0.54 [ 0.06, 5.24 ]
Total events: 1 (Fluphenazine (oral)), 2 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
2 headache - short term (up to 12 weeks)
Conley 2005 5/12 7/13 100.0 % 0.77 [ 0.33, 1.79 ]
Subtotal (95% CI) 12 13 100.0 % 0.77 [ 0.33, 1.79 ]
Total events: 5 (Fluphenazine (oral)), 7 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
3 lethargy - short term (up to 12 weeks)
Conley 2005 3/12 4/13 100.0 % 0.81 [ 0.23, 2.91 ]
Subtotal (95% CI) 12 13 100.0 % 0.81 [ 0.23, 2.91 ]
Total events: 3 (Fluphenazine (oral)), 4 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
4 insomnia - short term (up to 12 weeks)
Conley 2005 5/12 3/13 100.0 % 1.81 [ 0.55, 5.98 ]
Subtotal (95% CI) 12 13 100.0 % 1.81 [ 0.55, 5.98 ]
Total events: 5 (Fluphenazine (oral)), 3 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
5 somnolence - short term (up to 12 weeks)
Conley 2005 4/12 5/13 100.0 % 0.87 [ 0.30, 2.49 ]
Subtotal (95% CI) 12 13 100.0 % 0.87 [ 0.30, 2.49 ]
Total events: 4 (Fluphenazine (oral)), 5 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Chi2 = 1.64, df = 4 (P = 0.80), I2 =0.0%
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Analysis 2.7. Comparison 2 FLUPHENAZINE (ORAL) vs RISPERIDONE, Outcome 7 Adverse effects: 3.
Gastrointestinal.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 2 FLUPHENAZINE (ORAL) vs RISPERIDONE
Outcome: 7 Adverse effects: 3. Gastrointestinal
Study or subgroup Fluphenazine (oral) Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 constipation - short term (up to 12 weeks)
Conley 2005 4/12 0/13 100.0 % 9.69 [ 0.58, 163.02 ]
Subtotal (95% CI) 12 13 100.0 % 9.69 [ 0.58, 163.02 ]
Total events: 4 (Fluphenazine (oral)), 0 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
2 diarrhoea - short term (up to 12 weeks)
Conley 2005 0/12 2/13 100.0 % 0.22 [ 0.01, 4.08 ]
Subtotal (95% CI) 12 13 100.0 % 0.22 [ 0.01, 4.08 ]
Total events: 0 (Fluphenazine (oral)), 2 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
3 dyspepsia - short term (up to 12 weeks)
Conley 2005 3/12 1/13 100.0 % 3.25 [ 0.39, 27.15 ]
Subtotal (95% CI) 12 13 100.0 % 3.25 [ 0.39, 27.15 ]
Total events: 3 (Fluphenazine (oral)), 1 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
4 nausea/vomiting - short term (up to 12 weeks)
Conley 2005 2/12 3/13 100.0 % 0.72 [ 0.14, 3.61 ]
Subtotal (95% CI) 12 13 100.0 % 0.72 [ 0.14, 3.61 ]
Total events: 2 (Fluphenazine (oral)), 3 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Chi2 = 4.61, df = 3 (P = 0.20), I2 =35%
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Analysis 2.8. Comparison 2 FLUPHENAZINE (ORAL) vs RISPERIDONE, Outcome 8 Adverse effects: 4.
Other adverse events.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 2 FLUPHENAZINE (ORAL) vs RISPERIDONE
Outcome: 8 Adverse effects: 4. Other adverse events
Study or subgroup Fluphenazine (oral) Risperidone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 urinary frequency - short term (up to 12 weeks)
Conley 2005 0/12 1/13 100.0 % 0.36 [ 0.02, 8.05 ]
Subtotal (95% CI) 12 13 100.0 % 0.36 [ 0.02, 8.05 ]
Total events: 0 (Fluphenazine (oral)), 1 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
2 orthostasis - short term (up to 12 weeks)
Conley 2005 2/12 5/13 100.0 % 0.43 [ 0.10, 1.83 ]
Subtotal (95% CI) 12 13 100.0 % 0.43 [ 0.10, 1.83 ]
Total events: 2 (Fluphenazine (oral)), 5 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.26)
3 increased appetite - short term (up to 12 weeks)
Conley 2005 2/12 3/13 100.0 % 0.72 [ 0.14, 3.61 ]
Subtotal (95% CI) 12 13 100.0 % 0.72 [ 0.14, 3.61 ]
Total events: 2 (Fluphenazine (oral)), 3 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
4 dizziness - short term (up to 12 weeks)
Conley 2005 1/12 3/13 100.0 % 0.36 [ 0.04, 3.02 ]
Subtotal (95% CI) 12 13 100.0 % 0.36 [ 0.04, 3.02 ]
Total events: 1 (Fluphenazine (oral)), 3 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 0.37, df = 3 (P = 0.95), I2 =0.0%
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Analysis 2.9. Comparison 2 FLUPHENAZINE (ORAL) vs RISPERIDONE, Outcome 9 Adverse effects: 5.
Average endpoint weight loss (kg) (skewed data).
Adverse effects: 5. Average endpoint weight loss (kg) (skewed data)
Study Intervention Mean(kg) SD N
short term (up to 12 weeks) short term (up t
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Adverse effects: 5. Average endpoint weight loss (kg) (skewed data) (Continued)
Conley 2005 Fluphenazine -2.6 5.7 13
Conley 2005 Risperidone -0.65 2.43 13
Analysis 2.10. Comparison 2 FLUPHENAZINE (ORAL) vs RISPERIDONE, Outcome 10 Leaving the study
early.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 2 FLUPHENAZINE (ORAL) vs RISPERIDONE
Outcome: 10 Leaving the study early
Study or subgroup Fluphenazine (oral) Risperidone Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 inefficacy - short term (up to 12 weeks)
Conley 2005 1/12 1/13 100.0 % 1.08 [ 0.08, 15.46 ]
Subtotal (95% CI) 12 13 100.0 % 1.08 [ 0.08, 15.46 ]
Total events: 1 (Fluphenazine (oral)), 1 (Risperidone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 FLUPHENAZINE (ORAL) vs QUETIAPINE, Outcome 1 Clinically important
response (defined by study).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 3 FLUPHENAZINE (ORAL) vs QUETIAPINE
Outcome: 1 Clinically important response (defined by study)
Study or subgroup Fluphenazine (oral) Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term (up to 12 weeks)
Conley 2005 2/13 3/12 100.0 % 0.62 [ 0.12, 3.07 ]
Subtotal (95% CI) 13 12 100.0 % 0.62 [ 0.12, 3.07 ]
Total events: 2 (Fluphenazine (oral)), 3 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 FLUPHENAZINE (ORAL) vs QUETIAPINE, Outcome 2 Global state: 1. CGI:
Average endpoint CGI-SI (high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 3 FLUPHENAZINE (ORAL) vs QUETIAPINE
Outcome: 2 Global state: 1. CGI: Average endpoint CGI-SI (high = poor)
Study or subgroup Fluphenazine (oral) Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Conley 2005 13 5.15 (1.28) 12 5.18 (0.98) 100.0 % -0.03 [ -0.92, 0.86 ]
Subtotal (95% CI) 13 12 100.0 % -0.03 [ -0.92, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 FLUPHENAZINE (ORAL) vs QUETIAPINE, Outcome 3 Mental state: 2a.
General - average endpoint score (BPRS total, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 3 FLUPHENAZINE (ORAL) vs QUETIAPINE
Outcome: 3 Mental state: 2a. General - average endpoint score (BPRS total, high = poor)
Study or subgroup Fluphenazine (oral) Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Conley 2005 13 51.85 (14.87) 12 53.83 (13.14) 100.0 % -1.98 [ -12.96, 9.00 ]
Subtotal (95% CI) 13 12 100.0 % -1.98 [ -12.96, 9.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 FLUPHENAZINE (ORAL) vs QUETIAPINE, Outcome 4 Mental state: 2b.
Positive symptoms - average endpoint score (BPRS positive sub-score, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 3 FLUPHENAZINE (ORAL) vs QUETIAPINE
Outcome: 4 Mental state: 2b. Positive symptoms - average endpoint score (BPRS positive sub-score, high = poor)
Study or subgroup Fluphenazine (oral) Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Conley 2005 12 3.85 (12) 13 17.46 (4.18) 100.0 % -13.61 [ -20.77, -6.45 ]
Subtotal (95% CI) 12 13 100.0 % -13.61 [ -20.77, -6.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.73 (P = 0.00019)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 FLUPHENAZINE (ORAL) vs QUETIAPINE, Outcome 5 Mental state: 2c.
Negative symptoms - average endpoint score (BPRS negative sub-score, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 3 FLUPHENAZINE (ORAL) vs QUETIAPINE
Outcome: 5 Mental state: 2c. Negative symptoms - average endpoint score (BPRS negative sub-score, high = poor)
Study or subgroup Fluphenazine (oral) Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Conley 2005 12 6.31 (2.43) 12 6.42 (2.94) 100.0 % -0.11 [ -2.27, 2.05 ]
Subtotal (95% CI) 12 12 100.0 % -0.11 [ -2.27, 2.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 FLUPHENAZINE (ORAL) vs QUETIAPINE, Outcome 6 Mental state: 2d.
Anxiety/depression symptoms - average endpoint score (BPRS anxiety/depression sub-score, high score =
poor).
Mental state: 2d. Anxiety/depression symptoms - average endpoint score (BPRS anxiety/depression sub-score, high score =
poor)
Study Interventions Mean SD N
short term (up to 12 weeks) short term (up t
Conley 2005 Quetiapine 10.25 3.70 12
Conley 2005 Risperidone 9.31 5.91 13
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Analysis 3.7. Comparison 3 FLUPHENAZINE (ORAL) vs QUETIAPINE, Outcome 7 Mental state: 2e.
Hostility symptoms - average endpoint score (BPRS hostility sub-score, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 3 FLUPHENAZINE (ORAL) vs QUETIAPINE
Outcome: 7 Mental state: 2e. Hostility symptoms - average endpoint score (BPRS hostility sub-score, high = poor)
Study or subgroup Fluphenazine (oral) Quetiapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Conley 2005 12 10.54 (4.68) 12 9.75 (3.31) 100.0 % 0.79 [ -2.45, 4.03 ]
Subtotal (95% CI) 12 12 100.0 % 0.79 [ -2.45, 4.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 FLUPHENAZINE (ORAL) vs QUETIAPINE, Outcome 8 Mental state: 2f.
Activation symptoms - average endpoint score (BPRS activation sub-score, high = poor).
Mental state: 2f. Activation symptoms - average endpoint score (BPRS activation sub-score, high = poor)
Study Intervention Mean SD N
short term (up to 12 weeks) short term (up t
Conley 2005 Qutiapine 7.33 2.77 12
Conley 2005 Risperidone 7.00 3.06 13
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Analysis 3.9. Comparison 3 FLUPHENAZINE (ORAL) vs QUETIAPINE, Outcome 9 Adverse effects: 1.
Anticholinergic effect.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 3 FLUPHENAZINE (ORAL) vs QUETIAPINE
Outcome: 9 Adverse effects: 1. Anticholinergic effect
Study or subgroup Fluphenazine (oral) Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 dry mouth - short term (up to 12 weeks)
Conley 2005 2/12 2/12 100.0 % 1.00 [ 0.17, 5.98 ]
Subtotal (95% CI) 12 12 100.0 % 1.00 [ 0.17, 5.98 ]
Total events: 2 (Fluphenazine (oral)), 2 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 blurred vision - short term (up to 12 weeks)
Conley 2005 2/12 2/12 100.0 % 1.00 [ 0.17, 5.98 ]
Subtotal (95% CI) 12 12 100.0 % 1.00 [ 0.17, 5.98 ]
Total events: 2 (Fluphenazine (oral)), 2 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 urinary hesitancy - short term (up to 12 weeks)
Conley 2005 2/12 2/12 100.0 % 1.00 [ 0.17, 5.98 ]
Subtotal (95% CI) 12 12 100.0 % 1.00 [ 0.17, 5.98 ]
Total events: 2 (Fluphenazine (oral)), 2 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.0, df = 2 (P = 1.00), I2 =0.0%
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Analysis 3.10. Comparison 3 FLUPHENAZINE (ORAL) vs QUETIAPINE, Outcome 10 Adverse effects: 2.
Central nervous system.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 3 FLUPHENAZINE (ORAL) vs QUETIAPINE
Outcome: 10 Adverse effects: 2. Central nervous system
Study or subgroup Fluphenazine (oral) Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 anxiety - short term (up to 12 weeks)
Conley 2005 1/12 1/12 100.0 % 1.00 [ 0.07, 14.21 ]
Subtotal (95% CI) 12 12 100.0 % 1.00 [ 0.07, 14.21 ]
Total events: 1 (Fluphenazine (oral)), 1 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 headache - short term (up to 12 weeks)
Conley 2005 5/12 5/12 100.0 % 1.00 [ 0.39, 2.58 ]
Subtotal (95% CI) 12 12 100.0 % 1.00 [ 0.39, 2.58 ]
Total events: 5 (Fluphenazine (oral)), 5 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 insomnia - short term (up to 12 weeks)
Conley 2005 5/12 3/12 100.0 % 1.67 [ 0.51, 5.46 ]
Subtotal (95% CI) 12 12 100.0 % 1.67 [ 0.51, 5.46 ]
Total events: 5 (Fluphenazine (oral)), 3 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
4 lethargy - short term (up to 12 weeks)
Conley 2005 3/12 2/12 100.0 % 1.50 [ 0.30, 7.43 ]
Subtotal (95% CI) 12 12 100.0 % 1.50 [ 0.30, 7.43 ]
Total events: 3 (Fluphenazine (oral)), 2 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
5 somnolence - short term (up to 12 weeks)
Conley 2005 4/12 3/12 100.0 % 1.33 [ 0.38, 4.72 ]
Subtotal (95% CI) 12 12 100.0 % 1.33 [ 0.38, 4.72 ]
Total events: 4 (Fluphenazine (oral)), 3 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
Test for subgroup differences: Chi2 = 0.52, df = 4 (P = 0.97), I2 =0.0%
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Analysis 3.11. Comparison 3 FLUPHENAZINE (ORAL) vs QUETIAPINE, Outcome 11 Adverse effects: 3.
Gastrointerstinal adverse effects.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 3 FLUPHENAZINE (ORAL) vs QUETIAPINE
Outcome: 11 Adverse effects: 3. Gastrointerstinal adverse effects
Study or subgroup Fluphenazine (oral) Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 constipation - short term (up to 12 weeks)
Conley 2005 4/12 4/12 100.0 % 1.00 [ 0.32, 3.10 ]
Subtotal (95% CI) 12 12 100.0 % 1.00 [ 0.32, 3.10 ]
Total events: 4 (Fluphenazine (oral)), 4 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 diarrhoea - short term (up to 12 weeks)
Conley 2005 0/12 2/12 100.0 % 0.20 [ 0.01, 3.77 ]
Subtotal (95% CI) 12 12 100.0 % 0.20 [ 0.01, 3.77 ]
Total events: 0 (Fluphenazine (oral)), 2 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
3 dyspepsia - short term (up to 12 weeks)
Conley 2005 3/12 1/12 100.0 % 3.00 [ 0.36, 24.92 ]
Subtotal (95% CI) 12 12 100.0 % 3.00 [ 0.36, 24.92 ]
Total events: 3 (Fluphenazine (oral)), 1 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
4 nausea/ vomiting - short term (up to 12 weeks)
Conley 2005 2/12 1/12 100.0 % 2.00 [ 0.21, 19.23 ]
Subtotal (95% CI) 12 12 100.0 % 2.00 [ 0.21, 19.23 ]
Total events: 2 (Fluphenazine (oral)), 1 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Test for subgroup differences: Chi2 = 2.44, df = 3 (P = 0.49), I2 =0.0%
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Analysis 3.12. Comparison 3 FLUPHENAZINE (ORAL) vs QUETIAPINE, Outcome 12 Adverse effects: 4a.
Other adverse events.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 3 FLUPHENAZINE (ORAL) vs QUETIAPINE
Outcome: 12 Adverse effects: 4a. Other adverse events
Study or subgroup Fluphenazine (oral) Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 dizziness - short term (up to 12 weeks)
Conley 2005 1/12 1/12 100.0 % 1.00 [ 0.07, 14.21 ]
Subtotal (95% CI) 12 12 100.0 % 1.00 [ 0.07, 14.21 ]
Total events: 1 (Fluphenazine (oral)), 1 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 increased appetite - short term (up to 12 weeks)
Conley 2005 2/12 3/12 100.0 % 0.67 [ 0.13, 3.30 ]
Subtotal (95% CI) 12 12 100.0 % 0.67 [ 0.13, 3.30 ]
Total events: 2 (Fluphenazine (oral)), 3 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
3 orthostasis - short term (up to 12 weeks)
Conley 2005 2/12 1/12 100.0 % 2.00 [ 0.21, 19.23 ]
Subtotal (95% CI) 12 12 100.0 % 2.00 [ 0.21, 19.23 ]
Total events: 2 (Fluphenazine (oral)), 1 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
4 urinary frequency - short term (up to 12 weeks)
Conley 2005 0/12 1/12 100.0 % 0.33 [ 0.01, 7.45 ]
Subtotal (95% CI) 12 12 100.0 % 0.33 [ 0.01, 7.45 ]
Total events: 0 (Fluphenazine (oral)), 1 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 1.00, df = 3 (P = 0.80), I2 =0.0%
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Analysis 3.13. Comparison 3 FLUPHENAZINE (ORAL) vs QUETIAPINE, Outcome 13 Adverse effects: 4b.
Other - average endpoint weight loss (average weight in kg) (skewed).
Adverse effects: 4b. Other - average endpoint weight loss (average weight in kg) (skewed)
Study Intervention Mean(kg) SD N
short term (up to 12 weeks) short term (up t
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Adverse effects: 4b. Other - average endpoint weight loss (average weight in kg) (skewed) (Continued)
Conley 2005 Fluphenazine -2.6 5.7 13
Conley 2005 Risperidone -0.65 2.43 13
Analysis 3.14. Comparison 3 FLUPHENAZINE (ORAL) vs QUETIAPINE, Outcome 14 Leaving the study
early.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 3 FLUPHENAZINE (ORAL) vs QUETIAPINE
Outcome: 14 Leaving the study early
Study or subgroup Fluphenazine (oral) Quetiapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 inefficacy - short term (up to 12 weeks)
Conley 2005 1/13 2/12 100.0 % 0.46 [ 0.05, 4.46 ]
Subtotal (95% CI) 13 12 100.0 % 0.46 [ 0.05, 4.46 ]
Total events: 1 (Fluphenazine (oral)), 2 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 adverse effects - short term (up to 12 weeks)
Conley 2005 0/13 2/12 100.0 % 0.19 [ 0.01, 3.52 ]
Subtotal (95% CI) 13 12 100.0 % 0.19 [ 0.01, 3.52 ]
Total events: 0 (Fluphenazine (oral)), 2 (Quetiapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
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Analysis 4.1. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 1 Clinically important
response (defined by author).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 1 Clinically important response (defined by author)
Study or subgroup Fluphenazine (oral) Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 short term (up to 12 weeks)
Dossenbach 1998 20/30 15/30 100.0 % 1.33 [ 0.86, 2.07 ]
Subtotal (95% CI) 30 30 100.0 % 1.33 [ 0.86, 2.07 ]
Total events: 20 (Fluphenazine (oral)), 15 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
2 medium term (13 to 26 weeks)
Dossenbach 1998 16/30 10/30 100.0 % 1.60 [ 0.87, 2.94 ]
Subtotal (95% CI) 30 30 100.0 % 1.60 [ 0.87, 2.94 ]
Total events: 16 (Fluphenazine (oral)), 10 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
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Analysis 4.2. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 2 Global state: 1. CGI:
Average change CGI-SI (high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 2 Global state: 1. CGI: Average change CGI-SI (high = poor)
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Dossenbach 1998 28 -1.2 (1.3) 27 -1.9 (1.4) 100.0 % 0.70 [ -0.01, 1.41 ]
Subtotal (95% CI) 28 27 100.0 % 0.70 [ -0.01, 1.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
2 medium term (13 to 26 weeks)
Dossenbach 1998 28 -1.3 (1.5) 27 -2.2 (1.4) 100.0 % 0.90 [ 0.13, 1.67 ]
Subtotal (95% CI) 28 27 100.0 % 0.90 [ 0.13, 1.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.021)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 4.3. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 3 Mental state: 2a.
General - average change score (BPRS total, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 3 Mental state: 2a. General - average change score (BPRS total, high = poor)
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Dossenbach 1998 27 -15.9 (16.2) 27 -23 (14.7) 100.0 % 7.10 [ -1.15, 15.35 ]
Subtotal (95% CI) 27 27 100.0 % 7.10 [ -1.15, 15.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.092)
2 medium term (13 to 26 weeks)
Dossenbach 1998 27 -16.5 (18.5) 27 -25.8 (15.9) 100.0 % 9.30 [ 0.10, 18.50 ]
Subtotal (95% CI) 27 27 100.0 % 9.30 [ 0.10, 18.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Chi2 = 0.12, df = 1 (P = 0.73), I2 =0.0%
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Analysis 4.4. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 4 Mental state: 2b.
General - average change score (PANSS total, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 4 Mental state: 2b. General - average change score (PANSS total, high = poor)
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Dossenbach 1998 27 -27.9 (26.8) 27 -39.9 (25.8) 100.0 % 12.00 [ -2.03, 26.03 ]
Subtotal (95% CI) 27 27 100.0 % 12.00 [ -2.03, 26.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.094)
2 medium term (13 to 26 weeks)
Dossenbach 1998 27 -29.5 (31.9) 27 -45.7 (27.1) 100.0 % 16.20 [ 0.41, 31.99 ]
Subtotal (95% CI) 27 27 100.0 % 16.20 [ 0.41, 31.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.044)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
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Analysis 4.5. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 5 Mental state: 2c.
Positive symptoms - average change score (BPRS positive sub-score, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 5 Mental state: 2c. Positive symptoms - average change score (BPRS positive sub-score, high = poor)
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Dossenbach 1998 28 -5.3 (6.2) 27 -7.6 (5) 100.0 % 2.30 [ -0.67, 5.27 ]
Subtotal (95% CI) 28 27 100.0 % 2.30 [ -0.67, 5.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
2 medium term (13 to 26 weeks)
Dossenbach 1998 28 -5.5 (6.7) 27 -8.4 (5.3) 100.0 % 2.90 [ -0.29, 6.09 ]
Subtotal (95% CI) 28 27 100.0 % 2.90 [ -0.29, 6.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.074)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
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Analysis 4.6. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 6 Mental state: 2d.
Positive symptoms - average endpoint score (PANSS positive sub-score, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 6 Mental state: 2d. Positive symptoms - average endpoint score (PANSS positive sub-score, high = poor)
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Dossenbach 1998 28 7.9 (9.4) 27 13 (7.9) 100.0 % -5.10 [ -9.68, -0.52 ]
Subtotal (95% CI) 28 27 100.0 % -5.10 [ -9.68, -0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
2 medium term (13 to 26 weeks)
Dossenbach 1998 28 7.9 (10.2) 27 13 (7.5) 100.0 % -5.10 [ -9.82, -0.38 ]
Subtotal (95% CI) 28 27 100.0 % -5.10 [ -9.82, -0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 4.7. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 7 Mental state: 2e.
Negative symptoms - average change score (BPRS negative sub-score, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 7 Mental state: 2e. Negative symptoms - average change score (BPRS negative sub-score, high = poor)
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Dossenbach 1998 28 -2.2 (3.4) 27 -3.4 (2.9) 100.0 % 1.20 [ -0.47, 2.87 ]
Subtotal (95% CI) 28 27 100.0 % 1.20 [ -0.47, 2.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
2 medium term (13 to 26 weeks)
Dossenbach 1998 28 -2.4 (4) 27 -4.1 (3.6) 100.0 % 1.70 [ -0.31, 3.71 ]
Subtotal (95% CI) 28 27 100.0 % 1.70 [ -0.31, 3.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 4.8. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 8 Mental state: 2f.
Negative symptoms - average change score (PANSS negative sub-score, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 8 Mental state: 2f. Negative symptoms - average change score (PANSS negative sub-score, high = poor)
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Dossenbach 1998 27 -6.3 (6.5) 27 -8.7 (6.1) 100.0 % 2.40 [ -0.96, 5.76 ]
Subtotal (95% CI) 27 27 100.0 % 2.40 [ -0.96, 5.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
2 medium term (13 to 26 weeks)
Dossenbach 1998 27 -7.4 (8.2) 27 -10.4 (7.6) 100.0 % 3.00 [ -1.22, 7.22 ]
Subtotal (95% CI) 27 27 100.0 % 3.00 [ -1.22, 7.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
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Analysis 4.9. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 9 Mental state: 2g.
General psychopathology - average change score (PANSS general psychopathology sub-score, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 9 Mental state: 2g. General psychopathology - average change score (PANSS general psychopathology sub-score, high = poor)
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Dossenbach 1998 27 -13.4 (13) 27 -19.6 (13.6) 100.0 % 6.20 [ -0.90, 13.30 ]
Subtotal (95% CI) 27 27 100.0 % 6.20 [ -0.90, 13.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.087)
2 medium term (13 to 26 weeks)
Dossenbach 1998 27 -14 (15.2) 27 -22.2 (13.9) 100.0 % 8.20 [ 0.43, 15.97 ]
Subtotal (95% CI) 27 27 100.0 % 8.20 [ 0.43, 15.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.039)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 4.10. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 10 Mental state: 2h.
Anxiety - average change score (HAMA, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 10 Mental state: 2h. Anxiety - average change score (HAMA, high = poor)
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Dossenbach 1998 27 -5.8 (7.2) 27 -9.8 (7.5) 100.0 % 4.00 [ 0.08, 7.92 ]
Subtotal (95% CI) 27 27 100.0 % 4.00 [ 0.08, 7.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
2 medium term (13 to 26 weeks)
Dossenbach 1998 29 2.6 (13.7) 30 -3.4 (9.9) 100.0 % 6.00 [ -0.12, 12.12 ]
Subtotal (95% CI) 29 30 100.0 % 6.00 [ -0.12, 12.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Chi2 = 0.29, df = 1 (P = 0.59), I2 =0.0%
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Analysis 4.11. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 11 Satisfaction with
treatment: 1. Average change score (DAI, low = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 11 Satisfaction with treatment: 1. Average change score (DAI, low = poor)
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Dossenbach 1998 26 -0.2 (2.6) 26 1 (1.9) 100.0 % -1.20 [ -2.44, 0.04 ]
Subtotal (95% CI) 26 26 100.0 % -1.20 [ -2.44, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
2 medium term (13 to 26 weeks)
Dossenbach 1998 26 -0.6 (1.9) 26 0.5 (1.7) 100.0 % -1.10 [ -2.08, -0.12 ]
Subtotal (95% CI) 26 26 100.0 % -1.10 [ -2.08, -0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
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Analysis 4.12. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 12 Adverse effects: 1.
General.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 12 Adverse effects: 1. General
Study or subgroup Fluphenazine (oral) Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 at least one adverse effect - medium term (13 to 26 weeks)
Dossenbach 1998 23/30 15/30 100.0 % 1.53 [ 1.02, 2.31 ]
Subtotal (95% CI) 30 30 100.0 % 1.53 [ 1.02, 2.31 ]
Total events: 23 (Fluphenazine (oral)), 15 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Fluphenazine (oral) Olanzapine
Analysis 4.13. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 13 Adverse effects: 2.
Anticholinergic effect.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 13 Adverse effects: 2. Anticholinergic effect
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 concomitant anticholinergic medication - average endpoint dosage (mg/d) - short term (up to 12 weeks)
Dossenbach 1998 30 1.09 (1.35) 30 0.2 (0.66) 100.0 % 0.89 [ 0.35, 1.43 ]
Subtotal (95% CI) 30 30 100.0 % 0.89 [ 0.35, 1.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.24 (P = 0.0012)
2 concomitant anticholinergic medication - average endpoint dosage (mg/d) - medium term (13 to 26 weeks)
Dossenbach 1998 30 1.67 (1.79) 30 0.59 (1.35) 100.0 % 1.08 [ 0.28, 1.88 ]
Subtotal (95% CI) 30 30 100.0 % 1.08 [ 0.28, 1.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.64 (P = 0.0083)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
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Analysis 4.14. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 14 Adverse effects: 3a.
Central nervous system.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 14 Adverse effects: 3a. Central nervous system
Study or subgroup Fluphenazine (oral) Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 insomnia - short term (up to 12 weeks)
Dossenbach 1998 6/30 0/30 100.0 % 13.00 [ 0.76, 220.96 ]
Subtotal (95% CI) 30 30 100.0 % 13.00 [ 0.76, 220.96 ]
Total events: 6 (Fluphenazine (oral)), 0 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.076)
Test for subgroup differences: Not applicable
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Analysis 4.15. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 15 Adverse effects: 3b.
CNS (LSEQ, low = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 15 Adverse effects: 3b. CNS (LSEQ, low = poor)
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 awakening from sleep average endpoint score - short term (up to 12 weeks)
Dossenbach 1998 26 1.5 (10.2) 27 4.2 (16.9) 100.0 % -2.70 [ -10.18, 4.78 ]
Subtotal (95% CI) 26 27 100.0 % -2.70 [ -10.18, 4.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
2 behaviour following wakefulness average endpoint score - short term (up to 12 weeks)
Dossenbach 1998 26 0.1 (11.6) 27 6.7 (15.4) 100.0 % -6.60 [ -13.92, 0.72 ]
Subtotal (95% CI) 26 27 100.0 % -6.60 [ -13.92, 0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
3 getting to sleep average endpoint score - short term (up to 12 weeks)
Dossenbach 1998 26 5.4 (18.2) 27 9.8 (18.1) 100.0 % -4.40 [ -14.18, 5.38 ]
Subtotal (95% CI) 26 27 100.0 % -4.40 [ -14.18, 5.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
4 sleep quality - average endpoint score - short term (up to 12 weeks)
Dossenbach 1998 26 6.7 (19) 27 12.8 (17.6) 100.0 % -6.10 [ -15.97, 3.77 ]
Subtotal (95% CI) 26 27 100.0 % -6.10 [ -15.97, 3.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Chi2 = 0.61, df = 3 (P = 0.90), I2 =0.0%
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Analysis 4.16. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 16 Adverse effects: 4a.
Extrapyramidal effects.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 16 Adverse effects: 4a. Extrapyramidal effects
Study or subgroup Fluphenazine (oral) Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 akathisia - short term (up to 12 weeks)
Dossenbach 1998 9/30 3/30 100.0 % 3.00 [ 0.90, 10.01 ]
Subtotal (95% CI) 30 30 100.0 % 3.00 [ 0.90, 10.01 ]
Total events: 9 (Fluphenazine (oral)), 3 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
2 hypertonia - short term (up to 12 weeks)
Dossenbach 1998 3/30 1/30 100.0 % 3.00 [ 0.33, 27.23 ]
Subtotal (95% CI) 30 30 100.0 % 3.00 [ 0.33, 27.23 ]
Total events: 3 (Fluphenazine (oral)), 1 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
3 tremor - short term (up to 12 weeks)
Dossenbach 1998 3/30 3/30 100.0 % 1.00 [ 0.22, 4.56 ]
Subtotal (95% CI) 30 30 100.0 % 1.00 [ 0.22, 4.56 ]
Total events: 3 (Fluphenazine (oral)), 3 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 1.35, df = 2 (P = 0.51), I2 =0.0%
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Analysis 4.17. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 17 Adverse effects: 4b.
Extrapyramidal effects - average change score (SAS, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 17 Adverse effects: 4b. Extrapyramidal effects - average change score (SAS, high = poor)
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Dossenbach 1998 30 2.8 (6.1) 30 -1.4 (3.5) 100.0 % 4.20 [ 1.68, 6.72 ]
Subtotal (95% CI) 30 30 100.0 % 4.20 [ 1.68, 6.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.27 (P = 0.0011)
2 medium term (13 to 26 weeks)
Dossenbach 1998 30 1.9 (6.8) 30 -2.1 (4.8) 100.0 % 4.00 [ 1.02, 6.98 ]
Subtotal (95% CI) 30 30 100.0 % 4.00 [ 1.02, 6.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.63 (P = 0.0085)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
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Analysis 4.18. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 18 Adverse effects: 4c.
Extrapyramidal effects - average change score (HAS, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 18 Adverse effects: 4c. Extrapyramidal effects - average change score (HAS, high = poor)
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Dossenbach 1998 29 4 (13.2) 30 -2.6 (8.7) 100.0 % 6.60 [ 0.88, 12.32 ]
Subtotal (95% CI) 29 30 100.0 % 6.60 [ 0.88, 12.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
2 medium term (13 to 26 weeks)
Dossenbach 1998 29 2.6 (13.7) 30 -3.4 (9.9) 100.0 % 6.00 [ -0.12, 12.12 ]
Subtotal (95% CI) 29 30 100.0 % 6.00 [ -0.12, 12.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 4.19. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 19 Adverse effects: 4d.
Extrapyramidal effects - average change score (AIMS, high = poor).
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 19 Adverse effects: 4d. Extrapyramidal effects - average change score (AIMS, high = poor)
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 short term (up to 12 weeks)
Dossenbach 1998 30 -0.2 (2.4) 30 -1.3 (2.4) 100.0 % 1.10 [ -0.11, 2.31 ]
Subtotal (95% CI) 30 30 100.0 % 1.10 [ -0.11, 2.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.076)
2 medium term (13 to 26 weeks)
Dossenbach 1998 30 -0.5 (2.4) 30 -1.6 (3.6) 100.0 % 1.10 [ -0.45, 2.65 ]
Subtotal (95% CI) 30 30 100.0 % 1.10 [ -0.45, 2.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 1.00), I2 =0.0%
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Analysis 4.20. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 20 Adverse effects: 5.
Other adverse events.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 20 Adverse effects: 5. Other adverse events
Study or subgroup Fluphenazine (oral) Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 weight gain - medium term (13 to 26 weeks)
Dossenbach 1998 0/30 5/30 100.0 % 0.09 [ 0.01, 1.57 ]
Subtotal (95% CI) 30 30 100.0 % 0.09 [ 0.01, 1.57 ]
Total events: 0 (Fluphenazine (oral)), 5 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable
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Analysis 4.21. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 21 Adverse effects: 5b.
Other adverse events.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 21 Adverse effects: 5b. Other adverse events
Study or subgroup Fluphenazine (oral) Olanzapine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 concomitant anxiolytics medication average dosage (mg/d) - short term (up to 12 weeks)
Dossenbach 1998 30 8.05 (11.54) 30 3.4 (5.52) 100.0 % 4.65 [ 0.07, 9.23 ]
Subtotal (95% CI) 30 30 100.0 % 4.65 [ 0.07, 9.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.046)
2 concomitant anxiolytics medication - average dosage (mg/d)- medium term (13 to 26 weeks)
Dossenbach 1998 30 11.4 (13.44) 30 5.3 (7.31) 100.0 % 6.10 [ 0.63, 11.57 ]
Subtotal (95% CI) 30 30 100.0 % 6.10 [ 0.63, 11.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
3 effects on physiology - supine systolic blood pressure (average in mmHg) - short term (up to 12 weeks)
Dossenbach 1998 30 -4.33 (14.96) 30 5.67 (17.01) 100.0 % -10.00 [ -18.11, -1.89 ]
Subtotal (95% CI) 30 30 100.0 % -10.00 [ -18.11, -1.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.016)
4 effects on physiology - supine systolic blood pressure (average in mmHg) - medium term (13 to 26 weeks)
Dossenbach 1998 30 -4.3 (15) 30 5.7 (17) 100.0 % -10.00 [ -18.11, -1.89 ]
Subtotal (95% CI) 30 30 100.0 % -10.00 [ -18.11, -1.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.016)
Test for subgroup differences: Chi2 = 19.91, df = 3 (P = 0.00), I2 =85%
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Analysis 4.22. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 22 Adverse effects: 5c.
Other (skewed).
Adverse effects: 5c. Other (skewed)
Study Intervention Mean(kg) SD N
weight gain (average weight in kg) - short term (up to 12 weeks) weight gain (ave
Dossenbach 1998 Fluphenazine 0.45 2.72 30
Dossenbach 1998 Olanzapine 2.43 3.83 30
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Adverse effects: 5c. Other (skewed) (Continued)
weight gain (average weight in kg) - medium term (13 to 26 weeks) weight gain (ave
Dossenbach 1998 Fluphenazine 0.04 3.21 30
Dossenbach 1998 Olanzapine 5.15 6.41 30
Analysis 4.23. Comparison 4 FLUPHENAZINE (ORAL) vs OLANZAPINE, Outcome 23 Leaving the study
early.
Review: Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Comparison: 4 FLUPHENAZINE (ORAL) vs OLANZAPINE
Outcome: 23 Leaving the study early
Study or subgroup Fluphenazine (oral) Olanzapine Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 inefficacy - short term (up to 12 weeks)
Dossenbach 1998 3/30 1/30 100.0 % 3.00 [ 0.33, 27.23 ]
Subtotal (95% CI) 30 30 100.0 % 3.00 [ 0.33, 27.23 ]
Total events: 3 (Fluphenazine (oral)), 1 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
2 adverse effects - medium term (13 to 26 weeks)
Dossenbach 1998 4/30 0/30 100.0 % 9.00 [ 0.51, 160.17 ]
Subtotal (95% CI) 30 30 100.0 % 9.00 [ 0.51, 160.17 ]
Total events: 4 (Fluphenazine (oral)), 0 (Olanzapine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Chi2 = 0.35, df = 1 (P = 0.55), I2 =0.0%
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